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The work described in this dissertation was performed between April 2013 and 
July 2017. The focus of the work was to study the expression, activity and 
regulation of the novel latent-TGF-β1 receptor named Glycoprotein-A repetitions 
predominant protein (GARP). Since its discovery in 1992, the scientific literature 
regarding GARP can be divided into three consecutive time periods; each of them 
emphasizes research on a specific aspect of the protein (Figure 1).  
Initially, GARP gene Lrrc32 was isolated from human breast cancer. GARP gained 
attention between 1992 and 2006 because of its gene amplification in the 
aggressive forms of human carcinomas such as breast cancer.  
In 2009 GARP was identified as a latent TGF-β1 receptor, expressed on immune 
cells, specifically on regulatory T cells and megakaryocytes/platelets. At this time, 
GARP is gaining much more attention from the scientific community as an 
activation marker of regulatory T cells and for its ability to regulate the 
bioavailability of TGF-β. More than 50 publications have been dedicated to 
understanding the importance of the GARP-Foxp3-TGF-β1 triad in tolerance from 
2009 to present.  
The last two years have marked the third period when GARP expression and the 
TGF-β related function have been implicated as direct promoters of oncogenesis.  
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Work of this dissertation started when the importance of GARP as a regulator of 
TGF-β bioavailability in Treg cells was discovered. Three specific aims have been 
proposed and subsequently addressed, centered on the roles of GARP in cancer, 
and together they constitute my PhD thesis: 
 Aim 1. Investigate the formation and function of a novel soluble GARP/latent 
TGF-β complex 
 Aim 2. Determine the expression and functions of GARP/TGF-β on cancer 
cells 
 Aim 3. Study the role of GARP/TGF-β axis in platelets in the context of 
cancer 
Of note, the work in Aims 2 and 3 have been summarized and published in the 
journals Cancer Research and Science Immunology, respectively. The manuscript 
related to Aim 1 is currently in preparation and will be submitted shortly for 
publication.  Because the purpose is to have a better understanding of GARP/TGF-
β axis through the aforementioned aims, the following introduction will cover 
several aspects of GARP protein structure and function. The importance of TGF-β 








Figure Preface-1: Timeline of literature review about GARP 
GARP literature can virtually be divided into 3 time windows; each emphasizes a 
specific aspect of GARP function: the first round of research focused on the 
characterization of gene and protein structure; the second round was dedicated to 
GARP function on Treg cells and tolerance; research during the third round 
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GARP encoded by the Lrrc32 gene is the cell surface docking receptor for 
latent TGF-β1 mostly expressed on regulatory T cells (Treg) and platelets. 
Although GARP has been extensively studied for the ability to enhance latent TGF-
β1 activation in the context of Treg, the expression and relevant functions on 
cancer cells and platelets had not been explored when this work started 4 years 
ago. In addition, a soluble form of GARP has been described as shed from the 
Treg cell surface; however, the mechanism to explain the soluble molecule 
formation and how it becomes biologically active remains elusive.   
The results contained in this dissertation cover several unknown aspects of GARP 
biology and shed light on GARP as a potential therapeutic target in cancer 
treatment and prognosis.  
The first part of the results section focuses on the mechanism behind the formation 
and the biological activity of soluble GARP. Here we describe two putative 
mechanisms that explain the generation of the soluble protein. The first 
mechanism is mediated by thrombin that enzymatically cleaves surface GARP to 
generate two cleaved products. The second mechanism is mediated by 
extracellular vesicles (EVs) secreted by cells, specifically exosomes, which include 
GARP/latent TGF-β as a complex. Importantly, this part of the thesis dissertation 
demonstrated the importance of integrins belonging to the alpha V family that 
mediate the endocytosis of soluble GARP (sGARP) in epithelial cells. 
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In the second chapter of the results section, I report that GARP exerts oncogenic 
effects, promoting immune tolerance by enriching and activating latent TGF-β1 in 
the TME. In collaboration with other members in Dr. Zihai Li’s laboratory, I found 
that human breast, lung, colon, and prostate cancers expressed GARP aberrantly. 
In genetic studies utilizing normal mammary gland epithelial and carcinoma cells, 
GARP expression increased TGF-β bioactivity and promoted malignant 
transformation in immunodeficient mice. In immunocompetent breast carcinoma–
bearing mice, GARP overexpression promoted Foxp3+ Treg cell activity, which in 
turn contributed in enhancing cancer progression and metastasis. Notably, 
administration of a GARP-specific monoclonal antibody, made by Dr. Zihai Li’s 
laboratory, limited metastasis in an orthotopic model of human breast cancer. 
Overall, these results define the oncogenic effects of the GARP–TGFβ1 axis in the 
TME and suggest mechanisms that might be exploited for diagnostic and 
therapeutic purposes. These results have been summarized and published in the 
journal Cancer Research in a paper entitled “Expression of TGF-β Docking 
Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast 
Cancer”1. 
In the third part of the result section, I focused on the role of platelet GARP. Here, 
I hypothesized that constitutive GARP expression on platelets enhances the 
activation of latent TGF-β1 released by platelets. This phenomenon is critical in the 
cross-talk between platelets and cancer cells where GARP promotes malignancy 
and resistance to therapy. Indeed, platelet-specific deletion of GARP-encoding 
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gene Lrrc32 blunted TGF-β1 activity at the tumor site and potentiated protective 
immunity against both melanoma and colon cancer. This work was recently 
published in Science Immunology in an article entitled: “Platelets Subvert T Cell 
Immunity Against Cancer via GARP/TGF-β Axis”2. 
Overall, the results included in this thesis demonstrate that 1) the formation of 
soluble GARP is mediated by two novel mechanisms that can be exploited for 
cancer immunotherapy; 2) GARP is expressed on cancer cells and has oncogenic 
properties; and 3) GARP/TGF-β axis on platelets reduces the efficacy of the anti-




Introduction & Significance 
 
I-A. GARP gene, protein and regulation 
 
GARP Gene  
 
 Garp gene Lrrc32 was first cloned  in human breast cancer  in 1992 3. In 
their studies on DNA amplification, Szepetowski and colleagues identified a new 
independent unit present in the telomeric region at 11q13-q14, that they named 
GARP. In situ hybridization studies revealed that murine Lrrc32 gene is localized 
on chromosome 7 in a conserved region between human and murine genome4. 
Interestingly, Lrrc32 gene locus is part of a 3-5 Mb chromosomic region frequently 
altered in human cancers. Specific Lrrc32 gene amplification was observed in 
primary and metastatic neck lymph nodes in oral squamous cell carcinoma5; also 
in prostate cancer, Lrrc32 amplification rate increases with the decrease of 
hormone sensitivity6. Conversely, deletion and rearrangement of Lrrc32 locus was 
described in two cases of hibernoma, thus unveiling the ambiguous behavior of 
Lrrc32 gene product in cancer7. Nucleotide blasting analysis showed that human 
and murine Lrrc32 gene have a similar structure, i.e.,  they share the 81% of 
homology and both comprise of two coding exons; the first exon encodes for the 
signal peptide and 9 amino acids, and the second exon encodes for the majority 





After gene isolation, human and mouse protein putative sequences were 
deciphered. GARP protein structure can be divided into 3 domains: the 
extracellular domain, which constitutes about 70% of the protein, the hydrophobic 
transmembrane domain, and the 15-residue long cytoplasmic domain. As part of 
the Leucine Rich Repeats-Containing (LRR) proteins family, the extracellular 
domain of GARP contains 20 leucine rich motifs divided into two groups by a 
proline rich region8.  Among the extracellular LRR proteins, GARP together with 
the Toll like receptors, GP1bα and GP1bβ, belongs to the LRR_Tollkin subfamily, 
a group of proteins important in inflammation9. As well as Toll like receptors, GARP 
requires the master chaperone gp96 for its folding and surface expression10,11. The 
proline rich region located between the LRR resembles the hinge domain of the 
latent TGF-β1 binding protein (LTBP-1). This domain confers flexibility to the 
protein and suggests that GARP might be involved in protein-protein 
interaction12,13. Additionally, as well as LTBP, GARP covalently disulfide links with 
Latency Associated Peptide (LAP): site specific mutagenesis from Cysteine  to 
Alanine demonstrated that Cys-192 and Cys-133, located on the 7th and 12th LRR 
respectively, are responsible for the disulfide linkage between GARP and Cys-4 of 
LAP14 (Figure 1-1). Despite the high homology in the extracellular domain, murine 
and human cytoplasmic tails show a 33% difference in the amino acid sequence, 
yet they both have a conserved tyrosine residue. Of interest, other members of 
LRR_Tollkin family, like TLRs, have a cytoplasmic phosphorylated tyrosine 
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involved in signal transduction, suggesting a possible tyrosine phosphorylation 



















Figure 1-1: Structure of membrane bound GARP/latent TGF-β1 complex.  
GARP protein is structurally divided into 3 domains based on its primary sequence: 
the extracellular domain, the transmembrane domain, and the intracellular domain. 
The extracellular domain contains two sets of 10 LRRs divided by a Proline Rich 
Domain. Two conserved Cys residules (Cys-192 and Cys-133) are located on the 
7th and 12th LRR, respectively, and are responsible for two disulfide linkages 
between GARP and Cys-4 of LAP of latent TGF-β. 
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Tissue Distribution and Cell Expression 
 
In human tissues, GARP is expressed in peripheral blood, placenta,16 and 
pancreas17 in a concentration higher than 10 ppm. At the cellular level, GARP 
expression has been reported for mesenchymal stromal cells18, Treg cells, 
megakaryocytes/platelets19 20, LAP+ T cells21, hepatic stellate cells, 22 and 
activated human B cells23. GARP is widely expressed on mouse lymphoid organs: 
on resting Treg in the spleen, in mesenteric lymph nodes (mLNs) and in peripheral 
lymph nodes (pLNs), in thymus, and in payer’s patches24. In accordance with gene 
expression, GARP protein is expressed on human breast cancer, lung, and colon 
cancer, where it correlates with tumor aggressiveness1. 
GARP protein has been described as a membrane bound soluble protein that is 
shed from the T cell membrane25. The possibility of a shedding process was first 
discussed by Roubin and colleagues in 1996 when, describing a GARP deduced 
amino acid sequence, they observed the presence of a hydrophobic leader 
sequence. They hypothesized that this domain might be the signal peptide for 
protein secretion8. Soluble GARP indeed is present in human plasma, yet the 










GARP Gene Regulation 
 
Upon TCR engagement, GARP expression is only restricted to Treg cells; 
no significant surface expression of GARP has been described in human or mouse 
conventional T helper (Th) cells. 19,27. Cell and context specific expression of 
GARP gene is the result of the interplay of two alternative promoters: upstream 
Promoter 1 (P1) and downstream Promoter 2 (P2). Both promoters drive GARP 
gene transcription; however, the variance in their methylation status in different cell 
populations dictates where, and under which conditions, GARP will be expressed. 
P2 is almost completely demethylated in both Treg and Th, yet only in Th is the 
transcription initiation from P2 blocked by several methylated CpG islands present 
in the downstream P1.  Also, by inhibiting binding with any transcription factors, 
the methylated CpGs maintain P1 in a closed chromatin configuration. In contrast, 
the less pronounced methylation status of P1 in Treg allowed the binding of Foxp3 
that remodels the promoter region towards an open configuration status. This 
allows the subsequent binding of NFAT and NF-kB for driving the transcription of 
the GARP gene28. A clear example of this Foxp3 mediated GARP expression is 
the conversion of tumor Th17 cells to ex-Th17 Foxp3+ cells that show upregulation 
of surface GARP as a transdifferentiation-associated marker29. Accordingly, Foxp3 
shRNA in Treg reduced surface GARP, yet GARP shRNA did not affect Foxp3 
expression30. Treg might not be the only cell population that experiences GARP-
Foxp3 co-regulation; human and murine megakaryocytes and platelets 
constitutively express both Foxp3 and the surface GARP/LAP complex. 
Interestingly, platelets upon activation upregulate both GARP and Foxp3: PAR4-
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AP increases surface GARP, while phorbol ester myristate acetate upregulates 
Foxp3 expression19,31,32. Although the simultaneous upregulation of GARP and 
Foxp3 needs to be demonstrated, these findings suggest that platelets are another 
subset where GARP and Foxp3 interdependence might play a role. Furthermore, 
human melanocytes simultaneously express Foxp3 and GARP33.  
Conversely, other reports indicate that Foxp3 is not required for GARP expression 
in Th cells upon TCR stimulation24.  For example, the expression of GARP/LAP in 
Foxp3- Helios+ Treg is additional confounding evidence. Thus, the 
interdependence of GARP and Foxp3 expression is an intriguing area that is far 
from being completely understood34.  
As discussed later, GARP is a latent TGF-β receptor that enhances furin-mediated 
pro-TGF-β cleavage, yet GARP expression is independent of both TGF-β and 
Furin24. 
Post-transcriptional regulation is another important checkpoint in GARP 
expression.  The distal part of the 3’ UTR region of GARP transcript is targeted by 
six miRNAs that decrease GARP protein expression. Among these six miRNAs, 
miR-142-3p is expressed 2.5 times more in Th cells than in Treg cells, and upon 
TCR stimulation, miR-142-3p  expression decreases in both T cell populations25. 
MiR-142-3p facilitates the formation of a complex that together with Argonaute 2 




1-B. GARP in TGF-β1 regulation and tolerance 
 
TGF-β1 in Cancer 
 
The importance of TGF-β1 is demonstrated by the lethal phenotype of the 
global TGF-β1 knockout mice: TGF-β1 null mice die within 3-4 weeks after birth 
due to multiorgan inflammation36. On the other hand, TGF-β1 induces a variety of 
malignant cellular phenotypes like invasion, loss of cellular adhesion, epithelial to 
mesenchymal transition, and metastasis37. Retrospective studies highlight that in 
late stages of cancer, TGF-β1 levels positively associate with aggressiveness and 
poor prognosis. Consistent with this notion, intense TGF-β1 expression has been 
positively correlated with metastasis in breast carcinoma, prostate cancer, and 
colorectal cancer.38,39 Additionally, aggressive forms of human cancers upregulate 
the production of TGF-β1, thus supporting their own growth in an autocrine and/or 
paracrine fashion.40 Consequently, TGF-β expressing cancer cells are constantly 
supported by a positive feedback loop and have a selective advantage against the 
tumoricidal natural and lymphocyte-activated killer cells.  TGF-β1 modulates the 
TME by favoring the evasion of cancer cells from immune-surveillance, by 
tempering both the anti-tumor innate and adaptive immunity41. With regard to 
innate immunity, TGF-β1 induces M2 macrophages polarization42 and inhibits NK 
cells and DC maturation43,44. Similarly TGF-β1 impairs the adaptive anti-tumor 
immunity by directly inhibiting the clonal expansion and cytotoxicity of the CD8+ T 
CTLs45,46. Furthermore, TGF-β1 indirectly attenuates CTLs by inducing the 
expression of Foxp3, which confers a regulatory and immune suppressive 
phenotype to CD4+ T cells47.  
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During tumorigenesis, TGF-β1 has a dual role: it can act both as a tumor 
suppressor and as a tumor promoter cytokine48,49. In breast cancer, for example, 
the dual role of TGF-β1 action appears to be cancer stage-specific: TGF-β1 
functions as a powerful tumor suppressor in early stage breast cancer, while 
behaving as an oncogene in aggressive and advanced stage mammary tumors. In 
the early stages of breast cancer development, TGF-β1 controls cell proliferation 
mainly by inhibiting cell cycle progression through G1-arrest and by inducing or 
activating cyclin-dependent kinase (cdk) inhibitors. However, in advanced stage 
mammary tumors, cells acquire a TGFβ-1 dependent immunosuppressive ability 
and a mesenchymal phenotype50. In metastatic breast cancer, TGF-β is the major 
contributor to lung and bone metastasis through Smad-dependent signaling 
pathway51: human breast cancer bone metastasis shows a Smad4-dependent 
activation of pro-metastatic genes52.  
 
GARP Enhances TGF-β Formation and Activation  
 
TGF-β is widely expressed in most tissues and exists in at least 4 different 
forms: 1) freely soluble TGF-β; 2) soluble TGF-β associated with LAP, known as 
latent TGF-β; 3) TGF-β-LAP-LTBP, latent TGF-β associated with large TGF-β 
binding protein (LTBP); and 4) membrane latent form of TGF-β53.  GARP 
monomers are expressed on the cell surface where they act as a latent TGF-β1 
receptor54. Three forms of TGF-β exist: TGF-β1, TGF-β2, and TGF-β3, encoded 
by 3 different genes; yet, TGF-β1 is the most studied among the three isoforms55. 
The close association with GARP seems to be almost uniquely limited to latent 
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TGF-β1, since latent TGF-β3 failed to bind to GARP, and latent TGF- β2 showed 
a much lower binding affinity19.  
As a very powerful cytokine, Robertson et al. refer to TGF-β as the “beast”56; its 
production and secretion consist of multiple tightly regulated steps, and 
interestingly, GARP plays a role in each of them.  First, TGF-β is synthesized and 
secreted by the Golgi as inactive homodimeric pro-proteins that are cleaved by 
furin-type proteases to generate a mature TGF-β. At this stage, the newly 
synthetized molecule is non-covalently associated with the LAP, referred to as 
latent TGF-β. A study from Sophie Lucas’ laboratory clearly demonstrated  that 
GARP increases the rate of pro-TGF-β cleavage in a furin independent manner25.  
Subsequently, latent TGF-β associates with the latent TGF-β binding protein 
(LTBP), creating the large latent complex (LLC)57. GARP can interfere with this 
association due to its higher affinity to latent TGF-β: when both GARP and LTBP 
are co-expressed in 293T cells, GARP outcompetes with LTBP for latent TGF-β 
disulfide binding at the Cys4. Interestingly, electron microscopy analysis showed 
that GARP and latent TGF-β association also can be mediated by non-covalent 
binding14. The nature and function of this weakly associated complex might 
mediate  TGF-β activation upon surface shedding58, as discussed below. 
Finally, the release of the biologically active peptide requires the proteolytic 
separation of the mature form of TGF-β from the LAP. Multiple mechanisms have 
been evoked to describe this critical step, where cell surface integrins are the main 
orchestrators. αVβ6 and αVβ8 can activate latent TGF-β through proteases-
dependent and protease-independent mechanisms. In the proteases, independent 
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mechanism integrins αVβ6 and αVβ8 bind to the latent TGF-β and, deforming the 
surface LAP, they mediate the releases of the mature form of TGF-β. In the 
protease-dependent mechanisms, integrins recruit metalloproteinases or serine 
proteases that cleave LAP and, subsequently, free TGF-β59,60. For example, 
thrombin mediates the activation of latent TGF-β bound to αVβ6 in a mouse 
pulmonary edema model61. Novel findings demonstrated that membrane bound 
GARP facilitates the protease independent TGF-β activation facilitating the 
formation of a complex together with αVβ6 integrins and latent TGF-β. Intriguingly, 
the association of the GARP/latent TGF-β complex with integrins does not disrupt 
the ring like structure of the pro-TGF-β, suggesting that the integrins interaction is 
essential, yet it is not sufficient for secretion of mature TGF-β14. This may indicate 
that, similarly to latent TGF-β alone, integrin binding to LAP predisposes the 
complex for the release of the active peptide; however, extra tensile force is 
required for the removal of the “straightjacket” elements of LAP62. This might 
explain why GARP/latent TGF-β complex does not release active TGF-β, yet is still 
able to activate TGF-β signal transduction, as shown in Treg63, B cells63 and TGF-
β reporter cell lines14.  
Integrins contribution also has been described in activated Treg, where αVβ8 
integrins are responsible for the release of latent TGF-β from the cell surface and 
for the formation of biologically active TGF-β64. Also in this case, the biological 
activity of TGF-β was not directly measured in culture medium, but it was indirectly 
measured by a Th17 induction co-culture system.  Intriguingly, integrins and 
membrane tensile forces do not explain the release of mature TGF-β from soluble 
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GARP (sGARP). This conundrum was partially unveiled by Fridrich and colleagues 
when they observed that mature TGF-β can be released from sGARP only when 
GARP and latent TGF-β are non-covalently associated58. However, the intimate 
mechanism is still obscure. 
 
GARP and Peripheral Tolerance 
 
As previously discussed, GARP promoter has a binding region for Foxp3, 
indicating that Treg-specific transcription factor is required for GARP expression.    
Accordingly, silencing Foxp3 in human Treg reduces surface GARP upon TCR 
stimulation. On the other hand, enforced expression of GARP in human Th endows 
cells with suppressive capability by upregulating several Treg signature genes like 
Foxp3, CD25, and CTLA427,65. These findings suggest that the tolerogenic Treg 
phenotype might be enforced by a positive feedback loop between GARP and 
Foxp3. Accordingly, in Treg cells which are differentiated in vitro, GARP sh-RNA 
partially impairs normal suppressive ability30. The critical role of GARP in tolerance 
is demonstrated by fatal inflammatory disease developed by mice with a Treg-
specific gp96 deletion. As mentioned above, gp96 serves as chaperone for GARP 
folding: its deletion prevents GARP/latent TGF-β expression on activated Treg and 
consequently the acquisition of a suppressive phenotype. Accordingly, the fatal 
phenotype is partially rescued by exogenous active TGF-β administration10. This 
work might give a mechanistic explanation for the atopic dermatitis manifested by 




In allergen-specific gut inflammation, injection of anti-GARP blocking antibody was 
sufficient to reduce the therapeutic effect of activated Treg cells67, while during oral 
tolerance, blocking IL-6 signaling in presence of TGF-β polarized CD4+ T cells 
versus a GARP+LAP+ Treg that was critical to maintain oral tolerance in a DHT 
(delayed type hypersensitivity) reaction model68. Furthermore, monoclonal 
GARP/latent TGF-β antibody blocks the autocrine production of active TGF-β in 
Treg restraining their immunosuppressive activity in xenogeneic GVHD69. In line 
with these results, sGARP has been proven useful as an anti-inflammatory 
therapeutic agent by sustaining regulatory T cells differentiation in two different 
models of xenogeneic GVHD67,70. In addition, allergic airway inflammation is 
mitigated by sGARP injections in a TGF-β dependent way71. Conversely, other 
reports indicate that Foxp3 is not required for GARP expression on Th cells upon 
TCR stimulation and that Foxp3+ Treg maintains the same suppressive phenotype 
even in absence of GARP24.  
 
GARP and Tumor Tolerance 
 
Although in inflammation-driven phenotypes GARP offers several 
therapeutic benefits, in tumor settings the tolerogenic Foxp3/GARP/TGF-β axis is 
a mediator of the immunosuppressive microenvironment that enhances tumor 
growth. Human ovarian cancer ascites are infiltrated with Foxp3+GARP+Treg29. 
Higher frequency of GARP+Foxp3+ Treg expression positively correlates with an 
elevated immunosuppressive and more aggressive phenotype in advanced 
hepatocellular carcinoma72.  Human melanocytes express and secrete membrane 
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bound GARP and sGARP, respectively, that skew M2 macrophages toward a 
polarized phenotype and constrain the proliferation of CTLs and the production of 
cytokines 33. GARP is highly expressed in human breast, colon, and lung cancer 
where GARP/TGF-β axis sustains primary tumor growth and distal metastasis 
formation.  Antibody mediated blocking of GARP and latent TGF-β interaction is a 
therapeutic strategy in a syngeneic mammary carcinoma model1. Likewise, LAP 
blocking antibody, that prevents secretion of active TGF-β, reduces tumor growth 
















1-C. Platelet GARP 
 
 Platelets and Cancer Bidirectional Activation 
When circulating through blood vessels with an intact and 
healthy endothelium, platelets remain in an inactivated state. However, any injury 
to the endothelium will expose platelets to molecules such as collagen, 
thromboxane A2, ADP, and thrombin that are present in the subendothelial 
matrices which will trigger the activation of platelets. Activated platelets express 
receptors like glycoprotein (GP) Ib IX-V, GP Ia/IIa, GP VI, and p-Selectin, which 
mediate the aggregation of platelets and clot formation. Furthermore, upon 
activation platelets secrete a “releasate” rich in α granules that contain over 300 
proteins74. Alan T. Nurden classified the proteins in the platelets releasate (PR) 
based on their biological activity in: metabolites like adhesive proteins, clotting 
factors, fibrinolytic factors, proteases and anti-proteases, growth and mitogenic 
factors, chemokines, cytokines, antimicrobial proteins, and membrane 
glycoproteins75. In addition to tissue homeostasis, these proteins are involved in 
the modulation of innate and adaptive immunity, in inflammation, and in major 
diseases like atherosclerosis, multiple sclerosis, and cancer.76  
The leaking tumor vasculature (the tumor is a wound that does not heal)77 causes 
adhesion and subsequent activation of platelets that, in response, secrete  several 
proteins that fuel tumor growth. This platelets-cancer loop is a vicious circle where 
activated platelets and growing tumor reciprocally feed and support each other. 78, 
In addition to the leaky vasculature, tumors have the ability to produce tissue 
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factors, ADP, and thrombin to activate the surrounding platelets through the 
peroxisome activation receptors (PARs) expressed by platelets. On the other 
hand, each activated platelet releases up to 80 α granules that secrete platelet 
derived growth factors (PDGFs) in tumor proximity. One of the most abundant and 
critical PDGFs is TGF-β.79-81 In cancer-driven platelets activation, TGF-β released 
by platelets supports primary tumor growth by mitigating anti-tumor immunity and 
promotes intravasation to neighboring blood vessels, thus facilitating the 
metastatic process82. Venous thromboembolism (VTE) is a direct consequence of  
the massive platelet activation that occurs in cancer patients83. This phenomenon, 
better known as, Cancer-Associated thrombosis, is the second most common 
cause of mortality in patients with cancer84. Epidemiological estimates show that 
the annual incidence of venous thromboembolism (VTE) in cancer patients may 
be as much as 500/100,000/year compared to ≈ 70–113 cases/100,000/year in the 
general population79. 
 
GARP on Platelets 
 
As mentioned before, GARP was first identified on activated regulatory T 
cells and platelets19. Despite the increasing knowledge about the role of GARP in 
regulatory T cells, little attention has been given until now to the role of GARP on 
platelets. It is not totally clear whether GARP plays a role in platelet activation and 
function, since two studies in two different animal models seem to contradict each 
other. A first study performed on Danio rerio (zebrafish) demonstrated that GARP 
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is important for thrombus initiation and tissue homeostasis: knockdown of the 
Lrrc32 gene resulted in spontaneous bleeding events.85 A second study, 
performed on a genetic mouse model where Lrrc32 is specifically knocked out from 
platelets and megakaryocytes, shows that GARP is not necessary for thrombus 
formation and clot retraction. Interestingly this last work shows that ex-vivo 
platelets activation triggers increase in GARP surface expression, indicating that 
















1-D. Thesis Significance  
 
GARP’s ability to maintain the peripheral tolerance in the steady state is 
now accepted, delineating a fascinating scenario where GARP imposes itself like 
a new marker of activated and fully suppressive Treg in a TGF-β dependent 
manner67.  
Conversely, several other aspects of GARP biology still need to be studied to have 
a complete understating of GARP function.  
First, this thesis addresses the mechanistic aspect of soluble GARP (sGARP) 
generation and function. sGARP is present in plasma26 and has anti-inflammatory 
functions in the xenograft model of GVHD70 and in allergic airway inflammation71, 
yet how sGARP is generated and how the biologically active TGF-β is released 
remain unknown. This thesis describes two possible scenarios in which 
sGARP/latent TGF-β complex can be released. sGARP is a vehicle of latent TGF-
β that eventually will become activated; thus, understanding the mechanism 
behind the generation of this soluble complex is a necessary step to control its 
presence and spread in diseases where TGF-β plays a major role. 
Second, it is known that the Lrrc32 gene is amplified in human aggressive 
carcinomas; however, no evidence of GARP expression had been reported when 
this thesis started.  Many tumors are TGF-β dependent environments, and GARP 
concomitant expression is a newly described phenomenon that gives more insights 
into TGF-β regulation on cancer cells. Also, this thesis explores the possibility that 
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GARP is a novel tumor biomarker as well as a target for anti-GARP antibody based 
therapy. 
Finally, regardless of the extensive study of GARP function on Treg, only one study 
about GARP on megakaryocytes and platelets occurred prior to the current 
thesis85. This first study showed that GARP on platelets is important for 
coagulation; however, other major platelet functions were not explored. The third 
part of this thesis investigates the function of GARP-specific platelets in 
physiological conditions and in the presence of tumor. The current study examines 
platelet GARP as a potential mediator and enhancer of the cross-talk between 
tumor cells and platelets. Given that platelets are the major TGF-β reservoir and 
GARP enhances TGF-β activation, we aim to extend the knowledge on the role of 












Materials and Methods 
Cell Lines 
 
 Pre-B cell line (70Z/3) was a gift from Dr. Brian Seed (Harvard University) 
86. 4T1, NMuMG, and NMuMG* were obtained from Dr. Philip Howe (Medical 
University of South Carolina).  NMuMG* subline with silencing of hnRNP E1 were 
described previously87. 70Z/3 was validated by flow cytometry using B cell lineage 
markers. MC38 tumor cells were obtained from Dr. Mark Rubinstein (Medical 
University of South Carolina). 293FT and other cell lines were purchased from 
ATCC. 4T1, NMuMG, HEK-293FT, B16-F1 and MC38 cells  were cultured in 
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 100 units/ml 
penicillin, and 100 μg/ml streptomycin in a humidified atmosphere of 95% air and 
5% CO2 at 37°C.  PreB cells were cultured in RPMI medium with 10% fetal bovine 
serum, 100 units/ml penicillin,100 μg/ml streptomycin, and 1% β-Mercapto Ethanol 
in a humidified atmosphere of 95% air and 5% CO2 at 37°C.  Cancer cells were 
authenticated by gene expression analysis, in vivo growth, and histology. All the 
lines were monitored for pathogens as per MUSC regulations, and we routinely 








BALB/c and NOD–Rag-1-/- mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Platelets-specific GARP KO were obtained by 
crossing Lrrc32flox/flox24 mice with Pf4-Cre mice88. C57BL/6 WT mice were 
purched from the Jackson Laboratory. All animal experiments were conducted 
under approved protocols by the Institutional Animal Care and Use Committee at 
MUSC.  
Generation of GARP-expression vectors 
 
GARP was amplified by PCR and subcloned between the BglII and HpaI 
sites in a MigR1 retroviral vector11. A cDNA construct for expression of the GARP-
Fc fusion protein (sGARP) was generated by joining the extracellular domain of 
GARP to the sequence encoding the Fc portion of murine IgG2a by PCR using the 
following primers: 
GARP-FC fusion forward: 
AAGGGAGGGCTGAAGAATGTCAACGGCGGAGGTGGGTCGGGTGGCGGC 
GARP-FC fusion reverse: 
GCCGCCACCCGACCCACCTCCGCCGTTGACATTCTTCAGCCCTCCCTT 
Plasmid containing mouse Fc domain of IgG1 were donated by Stephen 





Retrovirus production and cells spin infection 
 
Ecotropic GARP and sGARP retroviral particles were packaged into the 
Phoenix-Ecotropic cells in presence of Lipofectamine 2000 (Fisher)10,11. After 48 h, 
virus containing medium was collected, centrifuged at 3000 rpm for 10 minutes, 
filtered with 0.25 µm filter, and stored at -80°C. For the spin infection, 2 × 105 cells 
were suspended in 1 ml along with 8ug/ml of polybrene and centrifuged for 90 
minutes at 32°C and 3,200 rpm. 1 ml of fresh medium was then added to the cells. 
Cells were stably selected by culturing in the presence of Blasticidin 48 h post 
transduction for at least 72 h. 
 
Lentivirus production and transduction 
 
For mouse GARP and thrombin knockdown and control, scrambled 
lentivirus vector-expressing short hairpin RNA (shRNA) transcripts were purchased 
from Sigma-Aldrich (St. Louis, MO), and viral particles were produced in HEK293FT 
cells as described previously11,89. Briefly, 239 HEK cells were transiently 
transfected with recombinant DNA vector in the presence of Delta 8.9 and VSV-G 
plasmids. Subsequently, the cells were spin infected with lentiviral supernatants. 
The knockdown efficiency was assessed by RT-PCR (Applied Biosystems Step-






Purification of soluble GARP 
 
sGARP protein was purified in the Dr. Stephen Tomlinson laboratory. For 
purification of sGARP, MigR1 vector was transfected into Chinese hamster ovary 
(CHO) cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's 
instructions. Stably transfected clones were selected by blasticidin (5 µg/ml), and 
protein expression was quantified by SDS-PAGE and western blot under reducing 
conditions using anti–mouse GARP and anti–mouse Fc antibody.  Recombinant 
sGARP was purified from cell culture supernatants by protein A affinity 
chromatography (GE Health). 
Surface and intracellular Flow Cytometry 
 
All staining protocol, flow cytometry instrumentation, and data analysis were 
performed in single cell suspension. Cells were washed in FACS buffer twice, FcR 
blocking was performed 10 minutes at room temperature, and surface antibodies 
were applied for 30 minutes at 4°C in FACS buffer.  For transcription factors and 
cytokine analysis, cells were fixed and permeabilized using Foxp3/Transcription 
factor Set (eBioscience cat # 00-5523-00) according to the manufacturer’s protocol.  
Tumor infiltrating Lymphocytes (TIL) isolation  
For TIL isolation, tumors were resected, chopped in small parts, and 
enzymatically digested in 1% Collagenase at 37°C for 1 hour shaking at 250 RPM. 
Tumors were filtered to have a single cell suspension, and lymphocytes were 
separated by density gradient centrifugation using Histopaque 1083 (Sigma cat # 
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10831). Lymphocytes were then analyzed by surface and intracellular flow 
cytometry.  
Human tumor microarrays  
 
All human tumor microarrays (TMAs) were derived from formalin-fixed, 
paraffin embedded tissues collected at the Medical University of South Carolina 
(Charleston, SC). Each patient specimen in these TMAs was represented in two 
cores on the slide, and each core measured 1 mm in diameter. These patient 
specimens were available in a single core of 2 mm in diameter. Clinical and 
demographic information were obtained from the Cancer Registry of the Hollings 
Cancer Center at MUSC or provided by the commercial source. This study was 
approved by the Institutional Review Board (IRB) at MUSC. 
Immunohistochemistry (IHC) 
 
The mouse anti-human GARP (hGARP) antibody (ALX-804-867-C100, 
Enzo Life Sciences) was first verified by western blot using hGARP-transfected 
HEK-293 cells and by IHC with hGARP-transfected 70Z/3 cells. Both analyses 
demonstrated specificity of the antibody at 1:100 dilution. TMA slides were 
processed, and antigen retrieved as described previously90. For mouse IHC, tissue 
was either placed into OCT media for fresh frozen sections or fixed in 4% 
paraformaldehyde overnight. Fixed tissue was incubated in 70% ethanol overnight 
prior to paraffin embedding, then cut for hematoxylin and eosin (H&E) staining. For 
p-Smad-2/3 on fresh frozen tumor sections, 5 µm sections were fixed with 4% 
paraformaldehyde followed by incubation with 3% H2O2. To minimize nonspecific 
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staining, sections were incubated with the appropriate animal serum for 20 min at 
room temperature, followed by incubation with primary anti-p-Smad-2/3 antibody 
(EP823Y; Abcam) overnight at 4°C. Staining with secondary antibodies (Vectastain 
ABC Kit) was then performed before development using DAB substrate (Vector 
Labs SK-4100). The staining intensity of GARP and pSmad-2/3 was graded as 
follows with the sample identity blinded (0: negative; 1: faint; 2: moderate; 3: strong 
but less intense than 4; and 4: intense). 
Generation and characterization of anti-GARP antibody 
 
Four BALB/c mice were immunized with recombinant human GARP (R&D 
Systems, Minneapolis, MN) with Freund’s complete adjuvant, followed by boosting 
with SP2/0 cells stably expressing human GARP for 2-3 times. Splenic B cells from 
mice with high anti-GARP antibody titers were fused to SP2/0 cells in the presence 
of polyethylene glycol. Hybridomas were selected in HAT medium and cloned by 
limiting dilution assay. The specificity of antibody was screened and determined by 
ELISA and flow cytometry using 70Z/3 cells stably transduced with empty vector 
(70Z/3-EV) and overexpression of human GARP (70Z/3-GARP).  
 
Protein extraction, immunoprecipitation, and western blot analysis 
Cells were harvested by trypsin-EDTA when necessary, washed in PBS, 
and lysed on ice in radio-immunoprecipitation assay (RIPA) lysis buffer in the 
presence of a protease inhibitor cocktail (Sigma-Aldrich). Nuclear-free protein 
lysate was quantified by Bradford assay (Bio-Rad), and an equal amount of lysate 
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was analyzed by SDS-PAGE and western blot under reducing conditions using 
anti–mouse GARP (AF6229; R&D system), anti-mouse Vimentin (D21H3; Cell 
signaling), anti-mouse E-Cadherin (24E10; Cell Signaling), and anti-mouse p-
Smad-2/3 (EP823Y; Abcam) antibodies. 
Cell proliferation and in vitro wound healing assay 
 
To measure cell proliferation, 2.5 x104 NMuMG* cells were seeded in a 96-
well plate in complete medium (DMEM, 10% FCS, 1% penicillin-streptomycin) and 
incubated overnight. Proliferation was determined with 3-[4,5 dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT), which was added to the cells at the 
indicated times and incubated for an additional 3 h at 37°C. The medium was then 
removed and mixed with 100 µl of DMSO for 15 minutes by shaking. Absorbance 
at 570 nm was then measured using a plate reader. The cell migration was 
measured by the wound-healing assay: at 100% confluence, two parallel wounds 
were made using a 1 ml pipette tip. Migration was assessed after 24, 48, and 72 
hours, and quantification of wound closure was measured using the ImageJ 
software (NIH). 
 
4T1 Tumor model, CD25+ cell depletion and GARP antibody therapy 
 
Female 6-8-week old BALB/c mice were inoculated in the fourth mammary 
fat pad subcutaneously (s.q.) with 5 x 105 cells (4T1-EV, 4T1-GARP, or 4T1-
sGARP). Tumor growth was monitored three times per week with a digital vernier 
caliper, and tumor volume was calculated using the following formula: tumor 
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volume (mm3) = [(width)2×length]/2. In GARP antibody therapy experiments, 
beginning at 3 days post-tumor inoculation anti-GARP antibody or isotype-
controlled antibody (0.1 mg/mouse in 0.1 mL PBS; three times per week) were 
administered intraperitoneally (i.p.) into mice. For combination therapy with 
cyclophosphamide (CY) and antibody, mice were treated with one injection of CY 
(4 mg/mouse) 3 days post-tumor inoculation in addition to the antibody treatment. 
For CD25+ cell depletion, mice received 500 g PC61 antibody via i.p. 
administration every 4 days, beginning 2 days before 4T1 injection. At end-point, 
mice were sacrificed, and the primary tumor, spleen, and lungs were isolated. 
Primary tumors were weighted, and IHC was performed. Lung macro- and micro- 
metastases were determined by visual inspection and microscopic analysis 
respectively. Tumor infiltrated lymphocytes were isolated by Collagenase D 
(Sigma) digestion followed by Histopaque-1083 (Sigma) mediated density 
separation.  
 
NMuMG tumor model 
 
Female NOD-Rag-1-/- (n=5 each group; 6-8 week old) mice were inoculated 
in the fourth and left mammary fat pad using 5 x 105 cells (NMuMG*-EV, GARP 
knockdown NMuMG*). Each week the animals were weighed, and tumors were 
measured. At endpoint, primary tumors, lungs, and livers were harvested. In 
another experiment: female NOD-Rag-1-/- mice (n=4-5 each group; 6-8 week old) 
were inoculated in the fourth left mammary fat pad with 5 x 105 cells (NMuMG-
GARP-Luc, NMuMG-sGARP-Luc or NMuMG-Luc cells). In vivo luciferase imaging 
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was conducted weekly as follows: mice were intraperitoneally injected with D-
luciferin (Perkin Elmer) at a dose of 150 mg/kg per mouse and anesthetized. 
Bioluminescence images were then acquired using the Xenogen IVIS imaging 
system. Bioluminescence signal was quantified as photon flux (photons/s/cm2) in 
defined regions of interest using Living Image software (Xenogen). 
GARP ELISA 
 
Plasma from prostate cancer patients and healthy controls were kindly 
donated by Dr. Michael Lilly and Dr. Jennifer Wu (Medical University of South 
Carolina). Samples were analyzed in duplicate according to the manufacturer’s 
protocols (BioLegend, San Diego, CA).  
GARP/TGF-β1 sandwich ELISA 
 
To measure GARP/TGF-β1 complex by ELISA, 96 well plates were coated 
with TGFβ1 capture antibody according to the manufacturer’s instructions 
(BioLegend, San Diego, CA). Samples were incubated for 2 h at room temperature 
followed by incubation with the anti-hGARP detection antibody developed by our 





Mice were anesthetized. A superficial incision was made approximately 1 
inch from the base of the tail. The incision was then blotted with Whatman paper 
every 10 seconds until bleeding ceased. The time from the incision to bleeding 
cessation was recorded. 
 
 
Actiavtion of platelets and Preparation of releasate from activated platelets 
 
Platelets-specific GARP KO and control mice were anesthetized, and blood 
was withdrawn to a 5 mL tube containing another 0.5 mL of acid citrate dextrose 
(ACD) buffer (39 mM citric acid, 75 mM sodium citrate, 135 mM dextrose, 1 μg/mL 
prostaglandin E1, pH 7.4). Samples were centrifuged for 10 min at 100 g, with no 
brake, and the upper layer of platelet-rich plasma was collected. Platelets were 
washed 2x with citrate washing buffer (128 mM NaCl, 11 mM glucose, 7.5 mM 
Na2HPO4, 4.8 mM sodium citrate, 4.3 mM NaH2PO4, 2.4 mM citric acid, 0.35% 
BSA and 50 ng/mL prostaglandin E1, pH 6.5), then resuspended in RPMI or PBS, 
enumerated by a blood cell counter, and diluted to a final concentration of 
1x108/mL. Purified platelets were incubated with or without mouse thrombin 
(Enzyme Research Laboratories, South Bend, IN)  for 1 hour at 37°C. Stimulated 
platelets were sedimented by centrifugation for 15 min at 3,200 g, and supernatant 




Platelets Releasate western blot  
 
Stimulated platelets with and without 1U/ml of thrombin were sedimented 
by centrifugation for 15 min at 3,200 g, and supernatant was collected. For 
reducing conditions, western blot PR was boiled for 5 minutes and loaded in the 
presence of dithiothreitol (DTT) and β-Mercaptoethanol. For non reducing and non 
denaturating western blot, no DTT and no β-Mercaptoethanol were used. Also 
samples were not boiled. 
 
Soluble TGF-β1 ELISA from Serum and Platelet Releasate  
 
Mouse serum samples were obtained from the lateral tail vein. Capture 
ELISA for TGF-β1 was performed according to manufacturer instructions 
(BioLegend, San Diego, CA). Blood was collected in Eppendorf tubes, allowed to 
coagulate for 30 minutes at room temperature, and centrifuged at 5,000 rpm for 15 
minutes.  Active TGF-β was measured with no additional manipulation. Total TGF-
β1 was measured following acidic activation using 1 M HCl for 10 min at room 
temperature, and neutralization occurred with 1.2 NaOH, 1 M Hepes.  Active TGF-
β1 and total TGF-β1 levels were measured using TGF-β1 ELISA kits according to 








WT or Plt-GARPKO mice were injected in the right flank with 1x106 MC38 
colon cancer cells. Tumor area was measured every 3 days with digital vernier 
caliper kinetically. Tumor infiltrating lymphocytes were isolated from fresh primary 
tumors by density gradient, after single cell suspensions were made with 
mechanics and enzymatic digestions as previuously described.  
 
B16-F1 model and Adoptive T cell therapy 
 
Treatment of B16-F1 melanoma by adoptive transfer of ex vivo activated 
Pmel T cells occurred as described previously91.  6-8-week old female C57BL/6J 
mice were inoculated subcutaneously (s.q.) in the right flank using 2.5 x 105 cells 
and, where specified, treated with one intra-peritoneal injection of 
cyclophosphamide (CY, 4 mg/mouse) one day prior to adoptive T cell therapy 
(ACT). To obtain gp100-specific T cells, the splenocytes from Pmel1 TCR 
transgenic female mouse were stimulated with hgp100 (25-33 epitope, 1 µg/ml, 
American peptide Company) and mouse IL-12 (10 ng/ml, Shenandoa) for 3 days. 
ACT occurred through tail vein injection of 2x106 activated Pmel T cells per 
recipient mouse one day after injection of CY. Growth of primary tumors was 
monitored three times per week with vernier calipers. Peripheral adoptively 
transferred Pmel cells were monitored at 2, 3, 4, and 5 weeks after ACT. Ex-vivo 
Pmel IFN-γ production was assessed by stimulating Pmel cells for 3 hours in the 




  Thrombin cleavage bloking experiment were performed using the following 
peptide: 
DLRENKLLHFPDLAVFPRLLIYLNVSNNLIQLPAGLPRGSEDLHAPSEGWSA 
 generated in Hangzhou Dangang biological technology (HangZhou, China). 
 
Dabigatran and Dabigatran Etexilate 
 
For in vivo experiments, mice daily received gavage 3mg/mouse of 
Dabigatran Etexilate (Boehriger Ingelheim) dissolved in water. For in vitro 
experiments, platelets were treated with 4 µg Dabigatran (Cayman) 
 
PD1 bloackade therapy 
 
 200 µg of anti mouse PD-1 blockade antibody (Bioxcell) were 




 Cell lysate was loaded, and SDS-PAGE was run. Gel was stained with 









 106 Pre-B cells were centrifuged and resuspended in thrombin buffer: 50 
mM Tris HCl pH 8.0, 100mM NaCl, 2.5 mM CaCl2, 0.1% β Mercapto Ethanol. Cells 
were digested for 2 h at room temperature with 4 µg of thrombin in 100 µl volume. 
Cells were then vortexed briefly, centrifuged, and lysed in RIPA buffer. 
 
Site direct mutagenesis 
 
Proline-Arginine at 267-268 and 286-287 amino acidic positions were both 
mutated to Alanine-Alanine using the QuikChange II XL Site-directed Mutagenesis 
kit (Stratagene). The following primers we used: 
267-268 point mutation forward: GGCCGTGTTCGCGGCACTCATCTACC 
267-268 point mutation reverse: GGTAGATGAGTGCCGCGAACACGGCC 
286-287 point mutation forward: GCGGGGCTGGCCGCAGGCAGTGAGG 
286-287 point mutation reverse: CTCACTGCCTGCGGCCAGCCCCGCA  
All constructs were subcloned into MigR1 retroviral vector for retrovirus 
production as previously reported11. The efficiency of mutagenesis was assessed 





RNA isolation and quantitative RT-PCR.  
RNA was isolated using Trizol reagent and analyzed by quantitative RT-
PCR with the following primers using SYBR Green reagent:  
Mouse Alpha V Forward: AGGTTGACCTCGCCGAAAAG 
Mouse Alpha V reverse: GCTGAACAATAGGCCCAACG 
Mouse beta 3 forward: TTACCACGGATGCCAAGACC 
Mouse beta 3 reverse: CCCCAGAGATGGGTAGTCCA 
Mouse beta 5 forward: CCGCTTAGGTTTCGGGTCTT 
Mouse beta 5 reverse: GGGACGCAGTTGGGGAATAA 
Mouse beta 6 forward: TCATAAAGCCAGTGGGGCTG 
Mouse beta 6 reverse: CCACACTGGAAGGAGCCATT 
Mouse beta 8 forward: CAACTGCATCCAGGAGCTGA 
Mouse beta 8 reverse: CAAGACGGAAGTCACGGGAA 
Mouse Thrombin forward: CCGTGTGTTTGCCAGACAAG 
Mouse Thrombin reverse: TTGGTTGTCCATGTCTCCCG 
Mouse GARP forward: CGCTTCGTCACCTGGATTTA 
Mouse GARP reverse: ATTGTGGGCCAGGTTAAGG 
   
 
NMuMG stimulation with soluble GARP and RGD peptide: confocal analysis and 
flow cytometry 
 
 Cells were stimulated with 5µg/ml of soluble GARP or multiple mouse IgG 
in serum free medium for 1 hour at 37° C. Cells were then washed and fixed only, 
or fixed and permeabilized using Image-iT Fix-Perm kit (Molecular probes). Anti- 
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mouse Alexa Fluor 594 conjugated antibody was used. For the RGD blocking 
experiment, 5ug/ml of RGD peptide was added to the cells 30 minutes before 
adding soluble GARP. For GFP- p-SMAD3 reporter vector92, transformed cells 
were stimulated with the indicated concentration of soluble GARP and analyzed 
by flow cytometry for GFP expression. 
 
Exosomes isolation  
 
HEK 293 cells were grown to confluence in T75 cm flasks, and complete 
medium was changed to serum-free medium for 24 h. Medium was collected and 
centrifuged at 2,000xg for 10 min, then supernatant was collected and centrifuged 
at 10,000xg for 30 min. Supernatant was further collected and centrifuged at 
100,000xg for 90 min. The pellet containing exosomes was suspended in RIPA 
buffer to solubilize proteins. Solubilized exosome proteins were quantified and 
subjected to SDS-PAGE and Western blotting.  
 
L-lactate measurement  
 
  Serum was deproteinizated with perchloric acid and subsequently 
neutralized with KOH. L-lactate concentration was then measured according to the 
manufactures instructions (Eton Bioscience).  
 





In TMAs where specimens were spotted in duplicate, the average of both 
cores was used as the representative value. The Student’s t-test was implemented 
to compare categorical variables such as normal versus cancer or different disease 
stages or categories. Kaplan-Meier analysis for correlation of GARP with survival 
was performed using X-tile software93. Population characteristics were tested for 
statistically significant differences between low and high GARP expressers using 
the Chi-square test. Tumor curve analysis was performed using 2-way analysis of 
variance (ANOVA) or a Wad test. For bioluminescence imaging study, random 
effects linear regression was used to model tumor volume over time.  To adhere 
to model assumptions, a square-root transform of tumor size was calculated before 
model estimation.  Bayesian information criteria were used to determine the best 
fitting model. The final model included three main effects of time and interactions 
between group and time. Wald tests were used to compare coefficients and 
significance across groups; all other experiments were analyzed using the Two-
tailed Student’s t-test with GraphPad Prism. All data are presented as mean ± 
SEM. P-values less than 0.05 were considered statistically significant. The Chi-
square test was used to analyze the correlation between high and low serum 
GARP, with the percentage of prostate cancer patients showing high PSA1 (higher 












GARP is a latent-TGF-β receptor expressed abundantly on Treg, platelets, 
and cancer cells. We and others have demonstrated that GARP can be shed form 
the cell surface and released extracellularly: plasma from prostate cancer patients 
contains GARP in association with TGF-β (See figure 4-8), platelets resealed 
GARP in platelets releasate (PR) (See figure 5-6), and GARP/latent TGF-β 
complex shed from T cell membrane25. The possibility of a shedding process was 
first discussed by Roubin and colleagues in 1996 when, describing GARP deduced 
amino acid sequence, the researchers observed the presence of a hydrophobic 
leader sequence. They hypothesized that this domain might be the signal peptide 
for protein secretion8, yet the mechanism for the protein’s shedding or secretion is 
not clear26. Although the mechanism of GARP secretion remains evasive, its 
immunosuppressive abilities have been already investigated. Soluble GARP, 
indeed, is an anti-inflammatory therapeutic agent that sustains regulatory T cells 
differentiation in two different models of xenogeneic GVHD67,70. In addition, allergic 
airway inflammation is mitigated by soluble GARP injections in a TGF-β dependent 
way71. In tumor settings, soluble GARP derived by cancer cells exerts its pro-
tumorigenic potentials by inducing a tolerogenic TME rich in TGF-β induced 
37 
 
Tregs1,33.  Soluble GARP therapeutic potentials in autoimmune diseases as well 
as its pro-tumorigenic activity in malignancies, prompted us to investigate how its 
formation occurs and how it is regulated.  
There are several mechanisms for the formation of a soluble protein, like 
alternative splicing that removes the transmembrane domain156 and surface 
shedding exerted by proteases157.  Our first observations led us to focus on a 
potential surface shedding of membrane bound GARP and to investigate the role 
of thrombin as enzyme involved in the protein’s cleavage.  
Thrombin is a trypsin like serine protease involved in the conversion of fibrinogen 
to fibrin. Phage display technology has shown that thrombin active site binds and 
cleaves a consensus recognition sequence containing Proline and Arginine158.   
As described herein, we performed site specific mutagenesis of putative thrombin 
binding sites on GARP to investigate the role of thrombin as potential enzyme 
involved in soluble GARP formation.  
Another elusive aspect is the mechanism that soluble GARP uses to elicit TGF-β 
signaling. Hahn and colleagues clearly showed that soluble GARP drives Treg 
induction; however, this effect was inhibited in presence of TGF-β receptor II 
blocking antibody70. These results indicate that mature TGF-β is released from 
soluble GARP/latent TGF-β complex in order to bind to its own receptor on the cell 
surface.  
Fridrich and colleagues observed that there are two forms of soluble GARP, one 
covalently and one non-covalently associated with latent TGF-β. The researchers 
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also observed that mature TGF-β can be released from soluble GARP only when 
GARP and latent TGF-β are non-covalently associated;58 however, how the 
release of active TGF-β occurs is not known. 
Lastly, another critical mechanism that cells utilize to secrete proteins is through 
the exosome machinery. These nanoscale vesicles of endocytic origins are 
secreted by most cells in the extracellular milieu where they travel until they fuse 
to the membrane of other cells. Exosomes mediate the inter-cellular 
communication carrying RNA, proteins, and DNA that can affect target cells159,160. 
Interestingly, tumor cells secrete exosomes containing oncoproteins that can 
mediate distant metastasis formation161.  
Herein we show evidence to support two mechanisms that involve soluble GARP 
formation: thrombin mediated shedding and exosome mediated GARP shedding. 












GARP is cleaved on the cell surface releasing a 29 KDa fragment in the 
extracellular environment. 
 
We demonstrated that the molecular chaperone gp96 is critical for cell 
surface expression of GARP and membrane latent TGF-β10. To investigate the role 
of gp96 in the formation of the soluble GARP, we expressed GARP in WT and 
gp96 KO Pre-B cells. Cell lysates analysis revealed the presence of three forms of 
GARP protein: full length protein (72 KD) expressed in both WT and gp96 KD cells, 
and 2 smaller forms of GARP protein (44 KD and 29 KD) not present in the gp96 
KD cells (Figure 3-1A). The formation of smaller fragments of GARP only in 
presence of gp96 supported the idea that GARP might be shed at the cell surface 
and be released in the extracellular environment. To address this possibility, we 
analyzed the presence of GARP in cell lysate and conditioned medium from GARP 
expressing cells. We observed that the 29 KD fragment was abundantly present in 
the conditioned medium, and only a small fraction of the protein was present as 
full length in the extracellular environment (Figure 3-1B). Mass spectrometry 
analysis showed that the 29 KD GARP fragment belongs to part of the N+ terminal 







Figure 3-1. GARP is cleaved on the cell surface.  
(A) Western blot analysis of GARP expressing Pre-B cells WT or gp96 KD.  Cell 
lysates were analyzed by using antibodies against mouse GARP and mouse gp96 
(B) Parallel western Blot analysis of cells lysates and conditioned media of Pre-B 
cells expressing GARP or control vector. (C) Mass spectrometry analysis of the 








Surface GARP is cleaved by thrombin. 
 
The next logical question that we asked aimed to define the mechanism of 
GARP cleavage. First, we tested the roles of furin, several matrix 
metalloproteinases, and serine protease inhibitors. We found that the lower GARP 
fragment decreased only when the serine proteases were inhibited (data not 
shown). In parallel, GARP amino acidic sequence was analyzed using the 
resource portal ExPASy to predict the potential proteases cleavage sites. Among 
the list of enzymes that were suggested to interact with GARP, thrombin attracted 
our attention for two reasons: first, thrombin is a surface serine protease; second, 
based on the ExPASy prediction, thrombin mediated cleavage generates two 
GARP fragments of the same molecular weight of the fragment that we already 
observed, 44 and 29 KD. (Figure 3-2A). For these reasons, we decided to continue 
studying the potential role of thrombin in GARP cleavage. We found that upon 
treatment with increasing concentration of thrombin, both 44 and 29 KD fragments 
increased in a dose dependent fashion (Figure 3-2B). Because GARP cleavage 
occurred in the presence and absence of serum in the conditioned medium (data 
not shown), we reasoned that thrombin was produced by the tumor cells. To 
address this point further, we knocked down thrombin in GARP expressing cells, 
and we noticed that the 29 KD GARP fragment was almost completely abrogated, 
while full-length protein staining intensity was increased (Figure 3-2C). In chapter 
5, GARP expression and function of platelets will be analyzed. Just like preB cells, 









Figure 3.2 Surface GARP is cleaved by thrombin. 
(A) GARP amino acidic sequence: The part in bold indicates the sequence found 
in the conditioned medium; the arrows indicate the predicted thrombin cutting sites 
based on ExPASy analysis. (B) GARP expressing Pre-B cells were digested with 
increasing concentration of thrombin (0, 1, 2, and 4 µg in 25 µl), followed by 
western blot analysis. (C) shRNA mediated KD of thrombin in Pre-B cells 
expressing GARP followed by western blot analysis. (D) Western blot analysis of 





GARP upregulates thrombin gene expression. 
 
Several cancers upregulate thrombin expression as a survival factor to 
amplify TCIPA as described in Chapter 5162,163. Moreover, as described in Chapter 
1, GARP exerts an oncogenic function in epithelial cells1. For these reasons, we 
next asked whether GARP expression could upregulate thrombin expression. 
Interestingly, enforced GARP correlated with enhanced expression of thrombin 
mRNA (Figure 3-3A), suggesting a positive correlation between GARP and 
thrombin gene transcription. In support of a GARP-thrombin correlation, we found 
a positive association (R=0.127) between GARP and thrombin mRNA in a cohort 

















Figure 3.3 GARP upregulates thrombin gene expression. 
(A) RT-PCR analysis of Lrrc32 and thrombin gene expression in Pre-B cells 
expressing GARP or control vector. (B) Regression analysis of GARP and 














Thrombin cleaves GARP at the amino acid position 267 and 286 between proline 
and arginine. 
 
To prove that thrombin cleaves GARP at the predicted cleavage sites, we 
mutated the two proline-arginine binding sites at 267-268 and 286-287 amino 
acidic positions to alanine-alanine. We thus generated 3 types of mutants: PR 267-
268AA (GARP 267), PR 286-287AA (GARP 286), and double mutant (DM) PR 
267-268AA PR 286-287AA (GARP 267-286, -DM). Previously, we showed that 
GARP cleavage occurs on the cell surface, so we decided to confirm that the 
mutations did not affect surface GARP expression.  Flow cytometry analysis 
showed that GARP harboring 267, 286, and both 267+286 (GARP-DM) mutations 
are normally expressed on the cell surface (Figure 3-4A). Strikingly, parallel 
western blot analysis of cell lysates and conditioned media revealed that thrombin 
indeed cleaves GARP at the predicted cleavage sites (Figure 3-4B). Notably, the 
smaller cleaved GARP fragment from GARP 267 and GARP 286 are reduced in 
molecular weight and intensity, yet are still present. The 29KDa fragment from 
GARP harboring the two mutations 267-286 (GARP-DM) is completely abrogated, 
indicating that thrombin cleaves GARP at both binding sites (Figure 3-4B). Next, 
we tested whether GARP-DM was resistant to the cleavage of exogenous 
thrombin.  To this end, we treated PreB GARP-WT and PreB GARP-DM with 
increasing concentration of thrombin.   As expected, both 44 and 29 KD fragments 
increased in a dose dependent fashion in GARP-WT, and no cleaved products 
were observed in GARP-DM (Figure 3-4C). To further confirm thrombin dependent 
GARP cleavage, we performed a competition assay using a recombinant fragment 
of GARP containing the two Proline Arginine thrombin binding sites, named T250 
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(Figure 3-4D). In accordance with the previous results, T250 competed with 
surface GARP in binding with thrombin and was able to reduce GARP cleavage 

















Figure 3-4 Thrombin cleaves GARP at the amino acid position 267 and 286 
between proline and arginine.  
(A) Surface flow cytometry analysis for GARP of WT PreB cells and GARP 
expression in PreB cells expressing WT GARP, GARP with single point mutation 
267 aa, GARP with single point mutation 286 aa, GARP with double point mutation 
267/286 aa (DM), and relative control vector. (B) Western blot analysis of cells 
lysates and conditioned media of PreB cells expressing WT GARP, GARP with 
single point mutation 267 aa, GARP with single point mutation 286 aa, or GARP 
with double point mutation 267/286 aa using antibody against GARP. (C) PreB 
cells expressing WT or DM GARP were digested with increasing concentration of 
thrombin (0, 1, 2, and 4 µg in 25 µl), followed by western blot analysis. (D) 
Recombinant fragment of GARP containing the two Proline Arginine thrombin 
binding sites (T250). (E) Western blotting analysis of GARP expressing PreB cells 




Thrombin-mediated cleavage facilitates latent TGF-β release from cell surface, 
yet does not affect mature TGF-β formation.  
 
GARP expression facilitates cleavage of pro-TGF-β1 in mature TGF-β1 and 
secretion of latent TGF-β 25. We hypothesized that thrombin mediated cleavage 
might be a mechanism to regulate the activation of latent TGF-β bound to GARP. 
A fundamental prerequisite was the binding of latent TGF-β to mutated GARP; 
thus, we checked if the mutations affected the ability of GARP to bind latent TGF-
β. Surface flow cytometry analyses showed that the 3 GARP mutants still retained 
the ability to bind to LAP, and interestingly, LAP binding increased in GARP-DM 
(Figure 3-5A). GARP has been shown to enhance pro-TGF-β maturation and to 
mediate latent–TGF-β secretion from Tregs25.  Thus, we decided to test whether 
thrombin plays a role in these two GARP functions. Surprisingly, the inhibition of 
thrombin-mediated cleavage did not affect the ability of GARP to facilitate pro-
TGF-β1 maturation (Figure 3-5B); however, such inhibition affected the secretion 
of latent TGF-β1 in the cell supernatant (Figure 3-5C). This result is consistent with 
the previous finding that thrombin cleavage occurs only on the cell surface and 
sheds light on the importance of thrombin in releasing latent TGF-β. Accordingly, 
low total TGF-β in conditioned medium of GARP DM correlated with the higher 
expression of LAP on the surface as shown by surface flow cytometry analysis 










Figure 3-5. Thrombin-mediated cleavage facilitates latent TGF-β release 
from cell surface yet does not affect mature TGF-β formation.  
(A) Surface flow cytometry analysis for LAP of WT PreB cells and GARP 
expression in PreB cells expressing WT GARP, GARP with single point mutation 
267 aa, GARP with single point mutation 286 aa, GARP with double point mutation 
267/286 aa (DM), and relative control vector. (B) Parallel western blot analysis of 
cells lysates and conditioned media of PreB cells expressing WT GARP, GARP 
with single point mutation 267 aa, GARP with single point mutation 286 aa, or 
GARP with double point mutation 267/286 aa using antibody against TGF-β. (C) 
Total TGF-β ELISA of conditioned medium of PreB cells expressing WT GARP, 
GARP with single point mutation 267 aa, GARP with single point mutation 286 aa, 
or GARP with double point mutation 267/286. Statistical significance was analyzed 





Recombinant GARP protein is bound to latent TGF-β and is cleaved by thrombin. 
 
To further study the function of GARP cleavage, we employed a 
recombinant form of soluble GARP (sGARP) where the transmembrane domain 
was replaced by IgG1 Fc fragment. The function of the Fc domain was to facilitate 
the protein purification using a Protein A column system. This recombinant protein 
mimics the soluble cleaved GARP product. Western blot analysis of the purified 
sGARP revealed that the recombinant protein was isolated in complex with latent 
TGF-β. Indeed, non-reducing and non-denaturating SDS-PAGE (ND) showed a 
large complex that was recognized at the same molecular weight by both anti-
GARP and anti-TGF-β antibody. When denatured and reduced (D), the complex 
dissociated in sGARP and TGF-β (Figure 3-6A). TGF-β ELISA of sGARP indeed 
showed that, at serial dilutions, sGARP corresponded with a parallel dilution of 
total TGF-β (Figure 3-6B). Soluble GARP/latent TGF-β complex was analyzed by 
western blot analysis upon dose dependent treatment with thrombin. As expected, 
digestion of soluble GARP with thrombin gave rise to 3 fragments: GARP full length 
(72 KD), and the 2 smaller fragments of 44 and 29 KD (Figure 3-6C). More 
interestingly, in parallel with the formation of cleaved GARP products, latent TGF-
β was released as represented by non-reducing conditions western blot analysis 
(Figure 3-6D). No active TGF-β dimer (25KDa) was detected by western blot 
analysis. Interestingly, GARP cleavage and latent TGF-β occurred in parallel, 
suggesting that GARP might be released in association with its own ligand. This 
disulfide-linked GARP-latent TGF-β complex has been already described as 
secreted from Treg surface25. The high amount of TGF-β bound to sGARP was 
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Figure 3-6. Recombinant GARP protein is bound to latent TGF-β and is 
cleaved by thrombin. (A) Western blot analysis of sGARP in reducing 
denaturating (D) and non-reducing non-denaturating (ND) conditions. Antibody 
against GARP and TGF-β were used. (B)Total TGF-β ELISA of 3 serial dilutions 
of soluble GARP-Fc. (C) Western blot analysis of 1µg soluble GARP digested with 
increasing concentrations of thrombin (0, 1, 2, and 4 µg in 25 µl) in reducing and 







Soluble GARP enhances TGF-β through αV integrins. 
 
We next studied how cleaved GARP/latent TGF-β binds to cell surface and 
enhances TGF-β activation. NMuMG SMAD3-GFP reporter cell line was 
stimulated with increasing sGARP concentrations. Remarkably, p-SMAD3 
signaling increased in response to sGARP in a dose-dependent fashion, as 
indicated by GFP signal intensity (Figure 3-7A). We then asked how latent TGF-β 
in complex with GARP was able to elicit TGF-β signal transduction. Integrins have 
been extensively studied for their ability to bind and to activate TGF-β59,164. In 
particular, αVβ6 and αVβ8 integrins have been shown to mediate TGF-β activation 
from membrane bound GARP in HEK293 and Treg cells, respectively. In 293 HEK, 
indeed, integrin αVβ6 binds to LAP’s RGD sequence of the membrane bound 
GARP/latent TGF-β and helps to release mature TGF-β14. Thus, it is plausible that 
integrins could mediate the binding and activation of latent TGF-β bound to 
sGARP.  By flow cytometry and RT-PCR analysis, we observed that αV integrins 
are abundantly expressed on NMuMG cells (Figure 3-7B and C). We next checked 
the expression of the β chains of integrins that have been reported to activate TGF-
β in vitro: αVβ6165, αVβ860, αVβ5166, and αVβ3167. Among the β integrins, β6 was 
the most expressed when compared to β3, β8, and β5 gene expression (Figure 3-
7C). Strikingly, the increasing concentration of RGD peptide was sufficient to 
decrease sGARP-dependent p-SMAD3 signaling in NMuMG, indicating that latent 







Figure 3-7. Soluble GARP enhances TGF-β through αV integrins. (A) Flow 
cytometry analysis of GFP p-SMAD NMuMG cells stimulated with soluble GARP. 
(B) Flow cytometry analysis of surface αV integrins in NMuMG cells. (C) RT-PCR 
analysis of αV and β integrins expressed on NMuMG cells. (D) Flow cytometry 
analysis of GFP expression in NMuMG cells stimulated with 8 µg of soluble GARP 









Soluble GARP/latent TGF-β complex is internalized by cells through integrins. 
 
Integrins bind to latent TGF-β on the cell surface where they predispose the 
complex for the release of the active peptide. We therefore attempted to detect 
soluble GARP complex on NMuMG cell surface. However, flow cytometry analysis 
and confocal pictures of NMuMG cells treated with soluble GARP or control IgG 
showed that after 1 hour of incubation, soluble GARP was not present as bound 
to the cell membrane (Figure 3-8A upper panel). Strikingly, we observed that 
sGARP was internalized as represented by flow cytometry analysis and confocal 
pictures of permeabilized NMuMG cells (Figure 3-8A lower panel). Integrins 
internalize ligands via receptor-mediated endocytosis. This is an interesting 
process that could give an alternative explanation to the integrin mediated surface 
release of active TGF-β168. Integrins’ contribution to both binding and 
internalization of soluble GARP was investigated by confocal analysis, which  
confirmed first that soluble GARP is internalized, and second that this process is 
abrogated by RGD peptide, suggesting that the interaction between LAP and 











Figure 3-8. Soluble GARP/latent TGF-β complex is internalized by cells 
through integrins. 
(A) Upper panel: surface flow cytometry analysis and confocal pictures of NMuMG 
cells stimulated with 1 µg of sGARP.  Lower panel: intracellular flow cytometry 
analysis and confocal pictures of NMuMG cells stimulated with 1 µg of sGARP. (B) 
Confocal pictures of fixed and permeabilized NMuMG cells stimulated with 1µg of 





GARP/latent TGF-β complex is released in exosomes. 
 
Western blot analysis of conditioned medium from GARP expressing cells 
indicated the presence of two cleaved products that, as shown earlier, resulted 
from thrombin mediated cleavage. Interestingly, a faint signal reflecting a full length 
of GARP was always detected, indicating that either the conditioned medium was 
contaminated by residues of whole cells, or GARP was released as a full-length 
protein. The consistent detection of these full-length proteins prompted us to 
investigate if exosomes release constitutes an alternative mechanism of GARP 
secretion. We hypothesized that GARP is an oncogenic protein that might be 
liberated via exosomes to increase the metastatic potentials of the cancer cells.  In 
support of this hypothesis, plasma collected from metastatic prostate patients 
revealed higher GARP concentration than non-metastatic patients. Additionally, 
following androgen deprivation therapy (ADT), we observed an important increase 
of soluble GARP concentration in the plasma of prostate cancer patients in parallel 
with a PSA1 decrease, suggesting GARP-rich exosomes are released upon 
cancer cell death (Supplemental Figure 2). Exosomes from 293 cells expressing 
TGF-β1 alone or in combination with GARP were isolated from serum free 
conditioned medium with serial ultracentrifugation and analyzed by western blot. 
Strikingly, a consistent concentration of GARP was detected (Figure 3-9A), and 
more importantly, immunoblot for GARP and TGF-β in non-reducing and non-
denaturating conditions revealed that exosomes contained GARP bound to TGF-
β (Figure 3-9B). The successful exosome isolations was demonstrated by 














Figure 3-9. GARP/latent TGF-β complex is released in exosomes. 
(A) Western blot analysis in reducing and denaturing conditions of exosomes 
isolated from conditioned medium of 293 HEK TGF-β with and without GARP 
expression. Anti-GARP antibody was used. (B) Western blot analysis in non-
reducing and non-denaturating condition of exosomes isolated from conditioned 
medium of 293 HEK TGF-β with and without GARP expression. Anti-GARP and 
anti-TGF-β antibodies were used. (C) Western blot analysis of CD63 in reducing 
and denaturing conditions of exosomes isolated from conditioned medium of 293 















GARP as a pro-oncogenic receptor for latent-TGF-β gene in epithelial cells has 
been described1. Numerous evidence suggests that GARP is secreted in 
combination with TGF-β; however, the generation of this soluble complex as well 
as its signal transduction pathway are completely unresolved. Herein, we provide 
evidence of two mechanisms that explain soluble GARP formation. The first 
involves the serine protease thrombin as the enzyme responsible for cleaving 
surface GARP to generate two soluble products: a C-terminal bigger fragment and 
an N+ terminal smaller one. We found that this latter fragment is abundantly 
released in the extracellular milieu. Then, we generated a recombinant GARP 
protein (sGARP) lacking the transmembrane domain to mimic the N+ terminal 
fragment that is released. We observed that sGARP is complexed with latent TGF-
β and drives Smad3 phosphorylation by binding to surface integrins through LAP. 
Additionally, our data showed that integrins are responsible for sGARP cell 
internalization. These observations shed light on a novel possible mechanism for 
active TGF-β release from GARP/latent TGF-β complex: our data propose the 
endocytosis-mediated internalization of sGARP bound to integrins and subsequent 
intracellular signaling. Integrins indeed can be endocytosed to release their cargo 
in the endosomes where they can be either recycled or degraded169. The 
endocytosis-mediated mechanism of TGF-β activation might explain the absence 
of active TGF-β release upon thrombin cleavage (See Figure 3-6D), yet the 
presence of Smad phosphorylation signaling is elicited by soluble GARP on 
NMuMG cells (See Figure 3-7A). GARP dependent TGF-β activation indeed, has 
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been mostly demonstrated by TGF-β reporter cell lines (mink lung epithelial 
reporter cells) and Smad 2/3 phosphorylation14,170.  
It is interesting that thrombin mediated activation of platelets leads to the secretion 
of active TGF-β through GARP (See chapter 5-6C and D); however, in cells with 
enforced GARP expression or in recombinant soluble GARP, thrombin cleavage 
causes release of latent TGF-β with no mature formed detected.  The apparent 
discrepancy might be explained by three hypotheses: 
1. Platelets express much more TGF-β than other cells. Thus, in cells other than 
platelets, the amount of active TGF-β produced is simply too low to be detected. 
2. Upon activation, platelets release lactic acid in their supernatant that might 
facilitate the disruption of the non-covalent bond between LAP and TGF-β1. The 
acid mediated activation of latent TGF-β has been described for osteoblasts during 
bone resorption171. Of note, serum from Pf4creGARPf/f mice contains elevated 
lactic acid levels (Supplemental Figure 2). This phenomenon might be interpreted 
as a consequence of sustained platelet activation to compensate for the low 
circulating active TGF β.  
3. Finally, there is a possibility that thrombin mediated cleavage requires thrombin 
binding to its receptor, largely expressed on platelets. Previous evidence, indeed, 
showed that PAR1 ligands can enhance activation of TGF-β bound to integrins 
through signals via RhoA and Rho Kinase61, suggesting that thrombin needs to 
bind to its receptor to activate TGF-β. 
61 
 
Another observation that deserves attention is the thrombin-mediated cleavage of 
platelet GARP. Thrombin directly elicits platelet activation by binding to thrombin 
G protein couple receptors PAR1 and PAR4, and additionally our data 
demonstrate that thrombin upregulates GARP expression and activation of TGF-
β. We also observed that thrombin releases soluble full length and cleaved GARP 
products in PR. These data strongly support the idea that thrombin-dependent 
GARP cleavage might be part of a novel mechanism to activate platelet membrane 
bound TGF-β.  
In parallel, the evidence that full-length GARP is present in the exosomes starts to 
unveil another important chapter of GARP biology. In this context, GARP/latent 
TGF-β complex in exosomes might be a system adopted by GARP expressing 
cancer cells and Treg to fill the extracellular environment with TGF-β and promote 
more tumor growth and more Treg conversion in a positive feedback loop. 
Interestingly, plasma of AML patients is rich in exosomes that carry pro-TGF-β and 
inhibit NKG2D expression on NK cells172. Additionally, cancer cells produce the 
so-called TuEx (Tumor derived Exosomes) that express membrane bound TGF-β 
and can induce Treg173. It is reasonable to think that these exosomes contain 
and/or express GARP/latent TGF-β and are used by cancer cells to guarantee an 
immunosuppressed environment.  
Of interest, Treg are among the lymphocytes that mediate many 
immunosuppressive effects by delivering miRNA and many other elements 
through exosomes174. Although this hypothesis has not been explored, it is 
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reasonable to assume that Treg derived exosomes contain GARP/latent TGF-β 
used to establish a paracrine feedback loop.  
GARP and TGF-β rich exosomes become attractive therapeutic agents. Exosomes 
have been employed as a drug delivery system in several diseases to transport 
siRNA175, chemotherapies176 and enzymes177. Cai and colleagues showed the 
efficacy of TGF-β1 rich exosomes produced by bone marrow derived dendritic cells 
(BMDC) in attenuating Th17 driven IBD (Inflammatory Bowel Disease) by inducing 
Treg178. Thus, it is reasonable to think that exosomes rich in GARP and TGF-β 
might be a useful tool in inflammatory diseases.  
Finally, we cannot exclude the possibility that thrombin cleavage and exosome 
release are two steps in the same pathway. It is possible, indeed, that soluble 
GARP/latent TGF-β complex is released upon thrombin cleavage and binds to the 
cell surface through integrins. After that binding, integrin mediated endocytosis 
could allow the intracellular sequestration of GARP and TGF-β that would be finally 
released in the exosomes.  









Expression of TGF-β Docking Receptor GARP 
Promotes Oncogenesis and Immune Tolerance 




GARP gene Lrrc32 was initially described as an amplified unit present in 
metastatic breast cancer. Subsequent studies showed that Lrrc32 amplification is 
not only restricted to advance breast cancer, but it is an hallmark in hormone-
resistant prostate cancer and metastatic oral squamous cells carcinoma as 
well3,5,6. Despite the multiple evidence of Lrrc32 amplification in cancer, GARP 
protein expression in breast cancer or in any other cancer was not investigated 
yet.   
Interestingly, the entire 11q13 region reveals the presence of a pool of 23 known 
genes frequently amplified in several human carcinomas94, however Lrrc32 is an 
independent unit since it does not require the amplification of the rest of the region 
to be extensively expressed. This aspect stimulated our interest and for this reason 
we decided to explore the oncogenic ability of GARP protein by enforcing its 
expression on mammary epithelial cells. We hypothesized that the single 
amplification of GARP gene was sufficient to initiate the mesenchymal transition 




This hypothesis is also reinforced by the existence of several cases of single gene 
amplifications which confer oncogenic properties to epithelial cells like for example  
Myc and HER2/neu95,96 in breast cancer.  
As a receptor involved in the maturation of TGF-β, the presence of GARP 
on cancer cells acquires an interesting meaning. Of note, Lrrc32 amplification was 
described in advanced stage cancers, when TGF-β acquires a pro-metastatic 
function. Indeed, histological analysis of primary breast97, lung (NSCLC)98, 
prostate99 and colon100 demonstrates that high TGF-β expression correlates with 
lymph node and distant metastasis. In this context, GARP might support cancer 
cells dissemination by providing an excellent reservoir of tumor TGF-β. 
Importantly, TGF-β produced by cancer cells exerts a paracrine function on the 
tumor microenvironment by regulating the innate and adaptive immune 
components and favoring tumor immune evasion. One of the most important 
mediators of tumor immune-tolerance are Treg, a cell population strongly induced 
in presence of mature TGF-β. It is not surprising that the accumulation of this cell 
type in TME inversely correlates with overall survival in several human solid 
tumors101. 
In the light of the pro-tumorigenic role of active TGF-β in late stage cancers, 
several clinical trials have been conducted to assess the efficacy of anti-TGF-β 
treatments102. Fresolimumab, for example, is a monoclonal TGF-β1, 2, and 3 
antibody used in phase 1 clinical trial in 28 advanced melanoma patients. The 
results show that 7 patients experienced stable disease and one achieved a partial 
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response103. The results from this and many other clinical trials show that better 
biomarkers are needed in order to select patients whose tumors express TGF-β. 
In this context GARP might be considered an excellent biomarker that identifies 
tumors that express membrane bound TGF-β. Secondly, because of its anti- or 
pro-tumorigenic nature, blocking TGF-β might stimulate more cancer cell 
proliferation if the treatment is performed in early tumors. As previously mentioned, 
Lrrc32 amplification has been described only in advance stage cancers where 
TGF-β acts as pro-metastatic cytokine, in this context GARP expression might be 
considered as a good candidate to define those cancers in which anti TGF-β 
treatment would be efficacious.   
Other than tumor biomarker, GARP on aggressive cancers becomes also a 
valuable target to add to the list of those used in antibody based therapy. 
Pertuzumab for example is a monoclonal antibody used in HER2 positive breast 
cancer104. Targeting GARP is a fascinating treatment option because it consents 
to attack cancer from two angles: first, the antibody would exert its tumoricidal 
effect directly on the cancer cells; second, immunosuppressive Treg expressing 
surface GARP would be specifically depleted, restoring an effective anti-tumor 
immunity. Several clinical trials have already demonstrating that targeting Treg 
using CD25 or CTLA4 monoclonal antibody enhances anti-tumor cytotoxic T cells 
response. However both CTLA4 and CD25 are not uniquely expressed only on 
activated Treg, upon activation CTLs express these two proteins on their surface 
as well and this might restrain the efficacy of the monoclonal antibody therapy105. 
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Among lymphocytes GARP expression has not been detected on any T effector 


































GARP expression and significance in mammary carcinoma 
 
Considering that TGF-β is highly expressed in infiltrating ductal 
carcinomas38 we first asked whether GARP might serve as a surface latent TGF-
β receptor in breast cancer. To examine GARP protein expression in archived 
formalin-fixed cancer specimens, we developed an immunohistochemistry (IHC) 
assay. The specificity of the anti-human GARP antibody was ascertained by its 
staining of a Pre-B leukemia cell line stably transfected with human GARP (Figure 
4-1A). Analysis of patient-matched uninvolved breast tissue versus primary breast 
cancer (n=16) indicated a significant increase of GARP expression on cancer 
tissues in 9 out of the 16 patients (Figure 4-1B and 4-1C). Consistent with previous 
findings, Lrrc32 mRNA expression was increased by ≥ 2-fold in 28.5% of patients 
with breast cancer (n=42) compared with normal breast tissues (data not shown), 
suggesting an amplification of Lrrc32 gene. In contrast with normal colon, lung and 
prostate epithelium, normal breast cancer shows a baseline GARP expression 
(Figure 4-1 B, 4-6 and 4-7) that might correlate with the baseline expression of 
TGF-β observed in normal mammary gland tissue106. Mammary gland 
development indeed requires a normal TGF-β signaling as shown by the lactation-
deficient phenotype of mice expressing a constantly activated TGF-βRI107. A 
growing body of evidences suggests a reciprocal inhibitory effects between 
Estrogen Receptor Alpha (ERα) and TGF-β in breast cancer:  while TGF-β restricts 
ERα mediated cell proliferation108, ERα suppresses TGF-β signaling cascade via 
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G protein couple receptor 30 (GPR30)109. Nevertheless, no association between 
GARP and ER, PR, HER2 expression was found (data not shown).  
As a receptor involved in the activation of its ligand, the presence of GARP on 
breast cancer acquires an interesting meaning. To understand the functional 
significance of GARP expression in mammary carcinoma, we screened murine 
mammary carcinoma cell lines for GARP expression by flow cytometry. A variant 
of the normal murine mammary gland epithelial cell line (NMuMG*), has been 
recently described as being capable of forming tumors in nude mice. In NMuMG* 
the RNA-binding protein hnRNPE1 is knocked down by RNA interference, inducing 
the constitutive translation of proteins involved in the epithelial to mesenchymal 
transition (EMT)110. Intriguingly, we found these cells expressed a significantly high 
level of endogenous GARP (Figure 4-1D-F), raising the possibility that heightened 
TGF- biogenesis, in addition to the silencing of the TGF--mediated translation 
repression complex, drives mammary cancer in this model. To test this hypothesis, 
we performed short hairpin RNA (shRNA) knock down (KD) of GARP in the 
NMuMG* cells (Figure 4-1D-F). GARP silencing did not affect the in vitro 
proliferation of NMuMG* cells as determined by MTT assay (Figure 4-1G). 
Remarkably, silencing of GARP alone in the NMuMG* cells significantly attenuated 
their growth in vivo (Figure 4-1H). Further, the ability of these GARP KD cells to 













Figure 4-1. GARP expression in human breast cancer and its oncogenic 
roles in murine mammary gland epithelial cells.  
(A) IHC validation of the human GARP antibody using Pre-B cells expressing 
human GARP or empty vector control. (B) Representative images of GARP IHC 
(brown color) of breast cancer with their respective patient matched normal tissue. 
Each patient specimen in these TMAs was represented in two cores on the slide 
and each core measured 1 mm in diameter. (C) Expression intensity of GARP-
positive cells in breast cancer specimens and patient matched adjacent normal 
tissue. (D) shRNA knockdown of GARP mRNA in NMuMG* cells. Cells treated with 
scrambled shRNA (SCR) were used as control. (E) Flow cytometry analysis of cell 
surface GARP expression on GARP KD and SCR NMuMG* cells. (F) Immunoblot 
of GARP and TGF-β level in GARP KD and SCR NMuMG* cells. (G) In vitro cell 
proliferation assay for GARP KD and SCR NMuMG* cells. (H) NMuMG* SCR and 
NMuMG*-GARP KD cells were injected into NOD-Rag1-/- mice, followed by 
weekly monitoring of the tumor growth kinetics (E). 120 days after tumor injection, 
lungs gross metastatic nodules were counted visually on the surface of the organ. 
**P<0.01. Statistical analysis was determined by 2-way ANOVA or two-tailed t-test, 










Enforced GARP expression in normal murine mammary epithelial cells 
upregulates TGF-β bioavailability and drives oncogenesis 
 
In the parental NMuMG cells, TGF-β exerts both a growth inhibitory 
response and an EMT response111. As such, NMuMG cells have been extensively 
utilized to study TGF-β signaling and biology 112. We found that stable GARP 
expression induced Smad-2/3 phosphorylation and expression of vimentin, but 
downregulated E-cadherin, consistent with increased canonical TGF-β signaling 
(Figure 4-2A). As previously mentioned, GARP can also be secreted as a soluble 
form and that soluble GARP can increase the bioavailability of TGF-β25,58,70. To 
further address this point, we generated a soluble GARP (sGARP) by fusing the 
entire ectodomain of GARP with the Fc portion of IgG (Figure 4-2B).  We found 
indeed that sGARP can induce EMT by inducing time- and dose-dependent 
upregulation of vimentin (Figure 4-2C). We next performed an in vitro “scratch” 
assay to gauge the migratory properties of GARP-expressing cells. The closure 
rate of the gap (created by scratching the culture plate) was significantly increased 
with GARP-expressing cells, indicating increased acquired migratory ability 
(Figure 4-2D and 4-2E). More importantly, we examined whether enforced GARP 
expression enabled NMuMG cells to establish tumors in vivo. To this end, female 
immunodeficient NOD-Rag1-/- mice were injected in the fourth mammary fat pad 
with GARP-expressing NMuMG cells or with EV control cells all of which were also 
engineered to co-express luciferase. By in vivo imaging of the bioluminescence, 
we found that the bioactive mass formed only in mice that received GARP+ or 
sGARP+ NMuMG, but not in mice receiving E- transduced cells (Figure 4-2F). This 
tumor formation by GARP-expressing cells was confirmed by histology (Figure 4-
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2G). Collectively, we demonstrate that GARP has a transforming property via 












Figure 4-2: Recombinant soluble GARP and enforced soluble GARP 
expression drives EMT and invasion on normal mammary gland epithelial 
cells. (A) Immunoblot analysis for GARP, E-cadherin, Vimentin and Smad2,3 
phosphorylation in NMuMG cells stably transfected with GARP vector or empty 
vector. (B) Immunoblot analysis for GARP in NMuMG cells stably transduced with 
GARP vector, sGARP vector or control vector. (C) NMuMG cells were treated for 
the indicated time points and with increasing doses of soluble GARP in serum-free 
culture medium, followed by immunoblot for vimentin.  (D) In vitro scratch assay to 
indicate the difference in the gap closure at 24 hours. (E) Summary statistics of 
three independent scratch assays. (F) In vivo imaging of the luciferin-enhanced 
bioluminescence in mice after injection of GARP, sGARP and control NMuMG 
cells, with representative images from Week 4. (G) Quantification of luciferase 
signal through the use of ROIs; data were weekly quantified by average radiance 
(photons/s/cm2/steradian). (H) Week 4 H&E and IHC analysis of Vimentin and E-
cadherin expression for membrane GARP expressing NMuMG tumors.  *P<0.05; 
**P<0.01. Statistical significance determined by two-tailed t-test. Western blot 
images are representative of 2 independent experiments and scratch assay are 





















GARP upregulation in murine mammary cancer cells promotes TGF-β activation, 
tumor growth, metastasis and immune tolerance   
 
Cancer-intrinsic TGF- signaling has been shown to promote breast cancer 
invasion and metastasis48,107,113. The other aspect of TGF- biology in cancer is its 
cancer-extrinsic role via modulating the host immune response 114, which is under-
studied. We thus turned our attention next to an examination of how GARP impacts 
cancer growth and metastasis in a syngeneic immune-sufficient setting. We chose 
the highly aggressive and metastatic 4T1 mammary carcinoma model in BALB/c 
mice 115. Similar to the NMuMG system, over-expression of GARP or sGARP in 
4T1 cells led to increased production of active TGF- (Figure 4-3A). One of the 
key mechanisms by which TGF-β inhibits tumor-specific immunity is via the 
induction of Foxp3+ Tregs. To this end, purified naïve CD4+ T cells were cultured 
in vitro with conditioned media from 4T1-GARP, 4T1-sGARP and empty vector 
(EV) control cells in the presence of polyclonal T cell activators for 3 days. The 
conditioned media from GARP-expressing cells was 2-3 fold more efficient at 
inducing Treg differentiation compared to medium from control cells (Figure 4-3B).  
We next injected 4T1-EV, 4T1-GARP and 4T1-sGARP cells orthotopically in the 
fourth right mammary fat pad of 6-8 weeks old female BALB/c mice. We found that 
GARP-expressing cells were more aggressive, as indicated by both increased 
growth kinetics of the primary tumor (Figure 4-3C and 4-3D) and increased lung 
metastasis (Figure 4-3E). We found that this aggressiveness correlated with 
enhanced TGF-β signaling in the tumor microenvironment as determined by 
increased p-Smad-2/3 in cancer cells (Fig 4-3F and 4-3G), as well as by expansion 
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Figure 4-3. GARP upregulation in murine mammary cancer cells promotes 
TGF-β activation, tumor growth, metastasis and immune tolerance. (A) 
Concentration of active TGF-β in 3 days conditioned medium measured by ELISA 
and immunoblot for GARP in 4T1 cells stably expressing GARP, sGARP, or EV. 
(B) Regulatory T cells differentiation assay using CD4+CD25- cells in the presence 
of 4T1-GARP, 4T1-sGARP, and 4T1-EV. (C) Female BALB/c mice were injected 
in the 4th mammary fat pad with 5x105 tumor cells. Tumor volume was measured 
every 3 days. (D) Three weeks after tumor injection, mice were sacrificed and the 
primary tumors were resected and weighted. (E) Lungs were isolated, paraffin 
embedded, and H&E stained for histological analysis. The number of micro-
metastatic tumor nodules in the lungs were enumerated by a pathologist. (F) 
Portions of the tumors were isolated and embedded in OCT and snap frozen. The 
fresh frozen sections were stained for the presence of p-SMAD-2/3; representative 
images are shown. (G) Summary statistics for p-SMAD-2/3 staining intensity, 
defined independently by a pathologist (S.S). (H) Tumor-infiltrating lymphocytes 
were isolated and the number of CD4+CD25+Foxp3+ Tregs were enumerated by 
flow cytometry. (I) Representative flow plots. (J) Summary of the percentage of 
Tregs in the tumor microenvironment. *P<0.05; **P<0.01; ***P<0.001. Statistical 
significance was determined by two-tailed t-test or Two-way ANOVA, where 















Depletion of CD25+ Treg cells abolished the aggressiveness of soluble GARP 
expressing mammary tumors  
 
To determine if the increased aggressiveness of 4T1-sGARP cells was 
mediated by Tregs, we next depleted CD25+ Treg cells with CD25-specific 
antibody PC61, followed by implementing either 4T1-EV or 4T1-sGARP (Figure 4-
4A). Indeed, Treg depletion abolished the aggressiveness of 4T1-sGARP 
measured by tumor growth kinetics (Figure 4-4B), as well as tumor volume (Figure 
4-4C). We also examined the tumor-infiltrating T cells, and confirmed that PC61 
injection resulted in reduction of CD4+CD25+ (Figure 4-4D) and 
CD4+CD25+Foxp3+ Tregs (Figure 4-4E), and increased percentage of IFN-
























Figure 4-4. Depletion of CD25+ T cells abolished the aggressiveness of 
soluble GARP expressing mammary tumors.  Experimental design. Female 
BALB/c mice received intra peritoneal injection of PC61 anti-CD25 monoclonal 
antibody (100 l ascites) every 4 days, starting 2 days before tumor injection. On 
Day 0 mice were injected in the 4th mammary fat pad with 5x105 tumor cells. Mice 
were sacrificed on day 15. (B) Tumor volume measured every 3 days. (C) Mice 
were sacrificed at day 15 after tumor injection and the primary tumors were 
resected and weighted. (D-E) Tumor-infiltrating lymphocytes were isolated and the 
number of CD4+CD25+ T cells, CD4+CD25+Foxp3+ Tregs were enumerated by flow 
cytometry. (F) Tumor-infiltrating CD8+ T lymphocytes were isolated, ex vivo 
stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin. IFNγ 




GARP is a novel therapeutic target in cancer 
 
We next determined whether GARP could serve as a novel therapeutic 
target in cancer, using an antibody-based strategy. The antibody was generated 
by Dr. Bill X Wu in Dr. Zihai Li’s laboratory. In brief, for the generation of anti-GARP 
monoclonal antibodies (mAbs), mice were immunized with recombinant human 
GARP, followed by boosting with irradiated whole myeloma SP2/0 cells stably 
expressing human GARP, with the aim of generating mAbs against GARP that 
were conformation-specific. More than 20 mAbs were generated that specifically 
recognize human GARP as determined by flow cytometry. All of these clones were 
specific for human GARP including clone 4D3 (Figure 4-5A) which also had a low 
level of cross-reactivity against mouse GARP (data not shown). Importantly, 4D3 
but none of the other clones, was able to block the binding of exogenous human 
LTGF-β1 (huLTGF-β1) to surface GARP (Figure 4-5B). To examine if GARP 
antibody had any direct anti-tumor activities in vivo, BALB/c mice were inoculated 
orthotopically with 4T1-GARP cells. Mice were then treated with either 4D3 (IgG1) 
or with isotype control antibody (ISO), either with or without a single dose of CY. 
This regimen was chosen because it was shown previously that a TGF-β-
neutralizing antibody 1D11 was able to potentiate the ability of CY to control 4T1 
116. We found that 4D3 did not inhibit the primary tumor growth (Figure 4-5C), but 
it significantly blunted lung metastasis compared with the isotype-treated group 
(Figure 4-5D). The reduction of lung metastasis was associated with decreased 
Tregs in the blood.  Concomitant treatment with chemotherapy and 4D3 resulted 
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in significant better control of primary tumors (Figure 4-5F and 4-6G), as well as 






















Figure 4-5. GARP-specific antibody has therapeutic value against preclinical 
model of breast cancer.   (A) Surface staining of pre-B cells stably expressing 
human GARP (pre-B-hGARP) by 4D3 GARP antibody.  Grey histogram represents 
staining with isotype control antibody. (B) pre-B-hGARP cells were incubated 
without or with human LTGF (huLTGF-), in the presence of GARP antibodies or 
Isotype control antibody, followed by staining for cell surface hLTGF-, in order to 
determine the activity of the antibody. (C) BALB/c mice were injected with 5x105 
4T1-hGARP mammary tumors orthotopically in the 4th mammary fat pad, followed 
by IP injection of 100 µg/ml of 4D3 GARP antibody every three days. The primary 
tumor growth kinetics were measured three times a week. Significance is indicated 
at various time points along the tumor curves. (D) Four weeks after tumor injection, 
mice were sacrificed. Lungs were isolated and the numbers of visual metastatic 
nodules were counted. (E) Spleens were harvested and percentage of Treg 
(FoxP3+CD25+CD4+) cells in the spleen of antibody treated mice versus Isotype 
antibody groups were determined by flow cytometry (F) BALB/c mice were injected 
with 5x105 4T1-hGARP mammary tumors orthotopically in the 4th mammary fat 
pad, followed by one dose of cyclophosphamide and IP injection of 200 µl of 4D3 
GARP antibody every three days. The primary tumor growth kinetics was 
measured three times a week. Significance is indicated at various time points along 
the tumor curves. (G) Five weeks after tumor injection, mice were sacrificed, 
tumors were excised and weighted. (H) Lungs were isolated and numbers of visual 
metastatic nodules were counted. *P<0.05; **P<0.01; ***P<0.001. Significance 
was determined by two-tailed T-test. Results are representative of two 
independent experiments.  
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Broad GARP expression in human cancers  
Finally, we reasoned that if GARP expression is an important mechanism 
for immune tolerance and oncogenesis, aberrant GARP expression shall not be 
restricted to the breast cancer. The recent cancer genomic revolution, including 
The Cancer Genome Atlas (TCGA) effort, indeed unveiled that Lrrc32 is amplified 
in up to 30% of patients with many human cancer types, including ovarian, lung, 
breast, and head and neck cancers (data not shown). By IHC, normal colonic 
epithelial cells showed no significant GARP positivity (Figure 4-6A). However, the 
primary colon cancers) and lymph node (LN) metastatic lesions stained variably 
positive for GARP (uniformly negative with isotype control antibody, data not 
shown) (Figure 4-6A). On a scale of 0 to 4, GARP intensity score ranged between 
0 and 3, averaging at 0.78 (p=1.1x10-8) in primary colon cancers and 1.18 
(p=0.003) in LN metastasis. More importantly, GARP levels correlated inversely 
with overall survival in patients with colon cancer, regardless of the pathological 
grade of tumors or lymph node status of the disease (Figure 4-6B). Similarly, we 
found significantly increased GARP levels in primary cancers of the lung and lymph 
node metastasis (Figure 4-6C), and higher GARP expression correlated with 
worse survival. Overall, we demonstrated for the first time that GARP is widely 
expressed in human cancers, suggesting that it is a general mechanism in 





Figure 4-6. GARP upregulation in human colon and lung cancer correlates 
with poor prognosis (A) Representative images of GARP IHC (brown color) of 
colon cancers with their respective patient matched normal tissue. Each patient 
specimen in these TMAs was represented in two cores on the slide and each core 
measured 1 mm in diameter. Expression intensity of GARP-positive cells in colon 
cancer is shown. (B) Correlation between GARP expression and overall survival 
of colon cancer. (C) Representative images of GARP IHC (brown color) of lung 
cancers with their respective patient matched normal tissue. Each patient 
specimen in these TMAs was represented in two cores on the slide and each core 
measured 1 mm in diameter. Expression intensity of GARP-positive cells in lung 
cancer is shown. (D) Correlation between GARP expression and overall survival 
of lung cancer.  *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. Statistical 
significance was analyzed by two-tailed T-test or Kaplan Meier Analysis; the 
number of samples (n) and are indicated 
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GARP is over-expressed in prostate adenocarcinoma and its levels positively 
correlate with Gleason score 
 
Lrrc32 gene amplification has been found in prostate cancers that 
progressed form hormone-sensitive to hormone-resistance117. Interestingly, 
prostate tumors secrete high amount of TGF-β, raising the possibility that similarly 
to breast, colon and lung cancer, prostate cancer also might express GARP. In line 
with this hypothesis plasma TGF-β positively correlates with tumor burden and 
presence of metastasis in prostate cancer patients118. Additionally the inhibition of 
TGF-β pathway specifically on prostate cancer cells suppresses the tumor 
progression to higher stage, suggesting that TGF-β exerts a pro-tumorigenic role 
on the same cells in an autocrine fashion119.  To test this hypothesis we tested for 
GARP expression in prostate cancer; 38 malignant and 15 adjacent normal 
specimens were immunohistochemically stained for GARP. In the adjacent normal 
group, 6 of 15 samples were negative and the rest only showed faint stain 
(Intensity=1). In turn, 6 of 38 cancer samples stained negative, and the remaining 
samples ranged from faint (Intensity=1) to intense (Intensity=4). Therefore, the 
average intensity was 0.6 in the normal group compared to 1.29 in cancer 
(p=0.0016). As for the average percent of positive cells, it was 26.7% in normal 
samples and 61.8% in cancer (p=0.0012) (Figure 4-7A and 4-7B) 
GARP expression also correlated with Gleason score, which is a measure of the 
grade of de-differentiation of the tumor; a higher Gleason score indicates a higher-
grade tumor. Tumors with Gleason scores 6-7 (n=16) had an average intensity of 
1.125, whereas those with Gleason scores 8-10 (n=22) averaged at 1.643 
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(p=0.036). In terms of tumor stage, we found a trend towards higher expression of 
GARP in stage III disease (n=30, Intensity=1.4) compared to stage II (n=8, 
Intensity=0.875), although the results did not reach statistical significance, likely 










































Figure 4-7: GARP is over-expressed in prostate adenocarcinoma and its 
levels positively correlate with Gleason score Representative images of GARP 
IHC (brown color) of prostate cancer with their matched normal prostate tissues. 
Each patient specimen in these TMAs was represented in two cores on the slide 
and each core measured 1 mm in diameter. Scale bar: 20 m B. Expression 
intensity of GARP-positive cells in prostate cancer specimens and patient matched 
adjacent normal tissue. C. Patient’s matched correlation between expression 





Soluble GARP is present in the plasma of prostate cancer patients and correlates 
with high PSA and presence of metastasis 
 
We also estimated the concentration of the soluble form of GARP protein 
(sGARP) in plasma of 48 prostate cancer patients and 6 healthy controls and found 
an increase in cancer patients (325.6 pg/ml ± 37.88) as compared to healthy 
controls (143.2 pg/ml ± 30.82) (Figure 4-8A). We then analyzed prostate cancer 
patients with sGARP concentration higher than 150 pg/ml and observed that 
78.5% of these patients had PSA higher than 10, and 57% presented secondary 
tumors (Figure 4-8B). 
Finally, we developed a unique sandwich ELISA to evaluate serum concentration 
of sGARP in complex with TGF-β (sGARP/TGF-β) and found that the 
concentration of the complex was higher in serum collected from prostate cancer 
patients compared to healthy controls (p=0.0305) (Figure 3-8C). 
Our results on prostate cancer show that histological presence of GARP 
expression on prostate tissue is a powerful diagnostic tool to use in combination 
and Gleason Score to ameliorate the current grading system for patients’ 
stratification. Moreover, soluble GARP present in plasma represents a useful and 







Figure 4-8: Soluble GARP is present in the plasma of prostate cancer 
patients and correlates with high PSA and presence of metastasis Soluble 
GARP ELISA performed on plasma samples collected in heparin coated tubes of 
prostate cancer patients and healthy controls. B. Correlation analysis between 
GARP positive or negative plasma samples with and high or low PSA1 (left panel), 
and percentage of metastasis (right panel). C. GARP/TGF-β sandwich ELISA 
performed on plasma samples collected in heparin coated tubes of prostate cancer 











Surface expression of TGF- in cancer has been recognized120,121, but its 
biological significance has remained elusive. This is in part due to lack of 
understanding of the molecular basis for membrane-bound TGF-. The discovery 
of GARP to be the sole cell surface docking receptor for latent TGF-β finally 
created an experimental opportunity to manipulate the level of surface TGF- 
through altering GARP. In this study, we demonstrated that the GARP/TGF-β axis 
plays both cancer-intrinsic and extrinsic roles in promoting oncogenesis. 
Using both human and mouse systems with a combination of genetic and 
immunological tools, we have made several fundamental discoveries in this study: 
(i) GARP is widely expressed by human cancer cells, but less so by normal 
epithelial cells; (ii) GARP expression and presence in plasma of cancer patients  
correlates with advanced stage of cancer and poor prognosis; (iii) GARP itself has 
a transformation potential, which renders normal mammary gland epithelial cells 
tumorigenic; (vi) GARP expression in cancer cells leads to increased TGF-β 
activity, likely due to its ability to concentrate LTGF-β in cis as well as in trans, 
contributing to cancer aggressiveness and metastasis; (v) GARP expression in the 
tumor microenvironment promotes the induction of Treg cells and thus blunts the 
function of effector T cells against cancers; and (vi) neutralizing GARP by blocking 
its ability to bind to TGF-β reduces tumor metastasis, even in the absence of 





Mechanistically, we discovered that GARP expression enhances TGF-β activation. 
We demonstrated this in both NMuMG and 4T1 that enhanced TGF-β activation 
translated into increased canonical signaling, such as phosphorylation of Smad-
2/3.  Importantly, the accumulation of active TGF-β within the tumor 
microenvironment impairs anti-tumor immunity through multiple mechanisms 
including the induction of Treg cells122,123. We investigated the latter utilizing a 
syngeneic tumor model, namely 4T1 mammary carcinoma (BALB/c). Our data 
indicate that GARP expression in 4T1 induces Treg cells which blunts the ability 
of effector T cells to control cancer. Thus, by positively regulating TGF-β in the 
tumor microenvironment, GARP promotes oncogenesis through cancer-intrinsic 
as well as cancer-extrinsic mechanism. 
The oncogenic roles of TGF-β span from promoting invasion, metastasis and 
angiogenesis, to maintaining stemness and inducing immune tolerance 48. Thus, 
TGF-β remains an attractive target for the treatment of cancer. However, the 
development of therapeutics that target TGF-β has thus far been hampered by 
multiple factors, not the least of which is the presence of multiple ligands in multiple 
forms and the context-dependent function of this pleotropic cytokine 124. Surface 
expression of GARP provides cancer cells a means to concentrate TGF-β locally 
and thus influence TGF-β-dependent growth, transformation and invasion through 
activation of both integrins and the TGF-β receptors. GARP therefore represents 
a unique alternative target for blocking the TGF-β pathway in the tumor 
microenvironment. In this study, we generated a panel of highly specific mAbs 
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against human GARP, and demonstrated that 1 of these mAbs, 5C5, with or 
without cyclophosphamide, successfully treated 4T1-hGARP tumors. We believe 
that GARP-targeted mAbs may exert their therapeutic benefits via three 
mechanisms: 1) inhibition of LTGF-β binding to GARP and thus blockade of TGF-
β biogenesis, 2) tumor-killing through antibody-dependent cell cytotoxicity (ADCC) 
and complement-dependent cell cytotoxicity (CDCC) and, 3) Ablation of 
immunosuppressive Treg cells. Interestingly, 4D3 clone is murine IgG1 isotype 
which has very limited ADCC and CDCC activities. Thus, the therapeutic effect of 
4D3 is likely through its ability to block the binding between LTGF-β and GARP, a 
speculation that is in part supported by reduction of Tregs in the tumor 
microenvironment. More importantly, unlike the systemic effect of anti-TGF-β 
blocking antibody, anti-GARP antibody would prevent the activation of TGF-β on 
the surface of GARP expressing cells, such as Treg and cancer cells. 
In conclusion, we have discovered that GARP is a novel oncogene due to its 
cancer-intrinsic roles in promoting invasion and metastasis, as well as its cancer-
extrinsic roles in inducing immune tolerance. It is a novel diagnostic and 









GARP/TGF-β axis on activated platelets 




Depending on the type and the aggressiveness of the tumor, the incidence 
of pulmonary embolism and deep venous thrombosis in cancer patients are twice 
the frequency of the same events in non-cancer patients125. This phenomenon was 
first described in the pioneering work of Armand Trousseau in 1865 when a close 
association was observed between deep vein thrombosis and advanced gastric 
malignancy126,127. Later studies named this process TCIPA:  tumor cells-induced 
platelets aggregation. Tumor cells indeed produce high level of blood coagulation 
factors like thromboxane A2, serine proteases, matrix metalloproteinase, 
prostacyclin, IL-6 and nitric oxide (NO) that stimulate platelets production, 
aggregation, activation and degranulation128,129. Platelets, in turn, confer to cancer 
cells a selective advantage by forming a “cloak” of fibrin that protects the tumor by 
the tumoricidal attack of NK cells130, neutrophils131, macrophages and CTLs132.  
Critical mediators of platelets-induced tumor growth are the α-granules released 
by platelets upon activation. By mass spectrometry analyses of Platelets 
Releasate (PR), we observed that one of the most abundant soluble factors 
secreted by platelets was TGF-β2. This was not surprising knowing that platelets 
are considered reservoirs of several bioactive molecules, however TGF-β was by 
far the most abundant among all the molecules present in PR. Interestingly, L-
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lactate concentration was significantly high in PR. We observed that PR contained 
both the latent and active form of TGF-β, and that the latter was the main 
suppressor of T cell mediated anti-cancer immunity2. The mechanism employed 
by thrombin stimulated platelets to release active TGF-β is not completed 
elucidated.  In the attempt to identify the enzyme involved in TGF-β maturation, 
Blakytny and colleagues, inhibited all the known latent TGF- β activators as serine 
proteinases, cysteine proteinases, thrombospondin1 and plasmin, yet none among 
those enzyme was responsible for mature TGF-β release in PR81;133. This might 
suggest that LAP and TGF-β dissociation is not mediated by proteases.  
Other than being the major reservoir of TGF-β, platelets are the only entity that 
constitutively express surface GARP, suggesting that the pool of platelet TGF-β is 
made by two fractions: one is stored in the  granules and released upon 
activation, the other is exposed on platelets surface through GARP. Of notes, it 
has been already described that two pools of TGF-β are secreted by active 
platelets, one pool is found in serum as large latent complex (LLC), while the other 
pool is initially retained in the fibrin clot as bound to LAP, subsequently when the 
plaque dissolves TGF-β gradually is activated and released134. Whether GARP is 
specifically involved in release and/or activation of TGF-β contained in one of the 
two pools, is not known.  
As an important modulator for the final step of TGF-β maturation14, we reasoned 
that GARP might participate in platelet derived latent TGF-β activation. Previous 
studies showed that GARP+Foxp3+ Treg correlates with immunosuppressive and 
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more aggressive phenotype in advance hepatocellular carcinoma72 and ovarian 
cancer29, yet the physiological function of platelet GARP in anti-cancer host 
immunity is completely unknown.   
In this chapter we employed a novel mouse model where the gene encoding for 
GARP was specifically knock-out in megakaryocytes and platelets. Additionally, 
the clinical potential of a targeted pharmacological therapy which reduces surface 
GARP on platelets was investigated.  
Anti-platelets regimens have been largely explored in cancer prevention and 
treatment. Acetyl salicylic acid (Aspirin), for example showed in several clinical 
trials to lower the short-term risk of cancer135,136. We have recently demonstrated 
that Aspirin in combination with Clopidogrel potentiate adoptive T cell therapy in 
B16 melanoma, yet alone these anti-platelets agents do not have significant anti-
tumor activity in our model2.  
Aspirin and Clopidogrel inhibit platelets activation by blocking the conversion of 
arachidonic acid to Thromboxane A2 and by acting as ADP receptor antagonist, 
respectively137. 
Here, to improve the efficacy of the anti-platelets therapy in cancer treatment we 
decided to block the most potent platelets activator, thrombin138, by using the 
thrombin inhibitor Dabigatran Etexilate, known as Pradaxa. Dabigatran has been 
FDA approved in October 2010 for the treatment and reduction of risk of deep vein 
thrombosis and pulmonary embolism. Its mechanism of action relies on the 
competitive and reversible binding to thrombin active site, thus impeding 
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coagulation factor-mediated thrombin activation. Interestingly, Dabigatran has 
anti-tumor properties in preclinical model of breast and pancreatic cancer139,140, 
yet the mechanism remains elusive.   
When compared to aspirin and Clopidogrel, Dabigatran presents several 
advantages: first by blocking directly thrombin, Dabigatran blocks the main 
mediator of the platelets activation141; second, Dabigatran directly inhibits 
thrombin-mediated conversion of fibrinogen to fibrin that leads to clot formation. 
Most importantly, dabigatran can still inactivate thrombin even when thrombin is 
fibrin-bound142,143. This latter function is critical in cancer because by blocking 
fibrin-bound thrombin, Dabigatran restrains the accumulation of active TGF-β in 
the fibrin plaque that surrounds and protects the tumor.   
In this chapter platelet GARP/latent TGF-β complex was studied and manipulated 

















GARP deletion on platelets does not alter platelets activation and number 
 
For the generation of mice with specific deletion of GARP on platelets the 
Cre-Lox recombination system was employed. Pf4creGARPf/f mice and their 
littermates were obtained by crossing GARP flox/flox with Pf4cre mice. Both mice 
have been previously described24,88. PCR analysis of genomic DNA demonstrates 
the deletion of Exon1 in both alleles of GARP gene in Pf4creGARPf/f mice (Figure 
5-1A). Phenotypical characterization of WT and Pf4creGARPf/f mice was 
performed by flow-cytometry analysis of GARP expression on CD41+ activated 
platelets. In Pf4creGARPf/f mice, GARP expression on platelets was totally 
abrogated (Figure 5-1B). One study performed on Danio rerio (zebrafish) 
demonstrated that GARP is important for thrombus initiation and tissue 
homeostasis85. To assess whether the function of murine platelets was 
jeopardized by GARP abrogation, we performed a bleeding time test on 
Pf4creGARPf/f and WT littermates. There was no statistically difference between 
the two groups (Figure 5-1C). This confirmed the finding of another group that in 
parallel with us showed that absence of GARP from platelets surface did not affect 
the ability of platelets to control hemostasis31. In our system, GARP deletion occurs 
in the megakaryocytes, platelets precursors144. To determine whether this might 
affect platelets generation, platelets count was performed, yet normal platelet 
number was observed in Pf4creGARPf/f mice (Figure 5-1D). Finally, thrombin-
mediated platelets activation was evaluated by p-Selectin expression. Upon 
thrombin ex-vivo stimulation both platelet GARP KO and WT upregulated p-
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Selectin as marker of platelets activation (Figure 5-1E). Overall these results 




































Figure 5-1. GARP deletion on platelets does not alter platelets activation and 
number.  A. Polymerase chain reaction (PCR) showing the excision of exon 1 from 
GARP gene that results in a smaller DNA fragment. B. Flow cytometry analysis 
showing the complete lack of expression of GARP in CD41+platelets. C. Little 
incision was performed on mice tail and bleeding time was evaluated. D. Periperal 
blood platelet count performed by scil Vet ABC instrument. E. Flow cytometry 
analysis to evaluate the p-Selectin expression of WT and GARP KO platelets upon 











Platelet-derived GARP/TGF-β complex blunts adoptive T cell therapy of 
melanoma 
 
So far we have shown that GARP is not critical for normal platelets number 
and function, however upon thrombin activation GARP is abundantly upregulated 
on platelets (Figure 5-6A), suggesting that it might play a role in active platelets 
beside thrombus formation. As explained earlier, platelets derived TGF-β plays a 
critical role in enhancing tumor progression, for this reason we challenged 
Pf4creGARPf/f and WT littermate mice with B16-F1 melanoma cells to investigate 
whether GARP, by enhancing TGF-β activation, might promote tumor progression. 
Surprisingly, tumors in both groups grew at the same rate and with the same 
aggressiveness (Figure 5-2A). Knowing that B-16-F1 is a poorly immunogenic 
tumor we asked whether GARP plays critically a roles in the tumor 
microenvironment by acting on the anti-tumor T cell immunity. This hypothesis was 
next addressed by comparing the efficacy of adoptive T cell therapy of melanoma 
in WT and Pf4creGARP f/f recipient mice. B16-F1 melanomas were established in 
either WT or Pf4creGARP f/f mice, followed by lymphodepletion with Cy on day 9, 
and the infusion of ex vivo activated Pmel T cells on day 10 (Figure 5-2B). Tumors 
were controlled much more efficiently in Pf4creGARP f/f mice compared with WT 
mice as represented by the tumor curve growth (Figure 5-2C) and survival (Figure 
5-2D). This was associated with longer persistency (Figure 5-2E) and better 
functionality (Figure 5-2F) of adoptively transferred Pmel1 cells in Pf4creGARP f/f 
mice peripheral blood. These results indicate that GARP on platelets decreases 
































Figure 5-2 Platelet-derived GARP/TGF-β complex blunts adoptive T cell 
therapy of melanoma. A. Tumor growth of WT and Pf4creGARPf/f mice (n=7-8) 
subcutaneously injected with B16-F1. B. Experiment design: on day 0. 
Splenocytes from Thy1.1+ Pmel transgenic mice were culture for 3 days and 
injected on day 10 in congenic Thy1.2 mice previously conditioned with Cy on day 
9. C. Tumor growth curves of mice. D. Kaplan-Mayer survival curve in B16-F1 
adoptively transferred bearing mice. E. The frequency of Pmel cells in mice was 
enumerated 3 weeks post-adoptive transfer of T cells by flow cytometry in the 
peripheral blood (CD8+Thy1.1+/total CD8+). F. IFN-producing ability of antigen-
specific donor T cells (Pmel) from indicated mice 3 weeks after T cell transfer. 
Repeated measures ANOVA was used in panel A and C. Two-tailed, independent 

















Platelet-intrinsic GARP plays critical roles in generating active TGF-β 
 
Systemic blockade of TGF-β signaling improves the effectiveness of 
adoptively transferred T cells145. Given that GARP enhances TGF-β activation and 
that platelets are the major reservoir of TGF-β, we decided to investigate TGF-β 
activation status as potential mechanism to explain the better anti-tumor activity 
observed in Pf4creGARPf/f mice. We observed that KO mice had a severe 
impairment in the activation of latent-TGF-β since they showed reduced active 





















Figure 5-3 Platelet-intrinsic GARP plays critical roles in generating active 
TGF-β. Serum levels of active A. and total B. TGF- were measured by ELISA in 
B16-F1 bearing mice (n=6-8 per group). Comparison was performed using two-













Targeting platelet-derived GARP/TGF-β complex improves MC38 tumor control 
 
 To further investigate the TGF-β driven phenotype that we observed using 
B16-F1 tumor model, we decided to employed MC38 colon carcinoma. In this 
model, indeed, tumor infiltrated CD8+ T cells functionality is severely impaired by 
TGF-β signaling146.  Interestingly the rate of tumor growth was the same in both 
groups in the first two weeks after tumor injection, only around day 15 the two 
curves started to separate showing a better tumor control by Pf4creGARP f/f mice 
(Figure 5-4A). This might indicate that platelets derived TGF-β has a potent 
immunosuppressive effect on the adaptive arm of the anti-tumor immunity. This 
was reflected also by the longer overall survival experienced by Pf4creGARP f/f 
(Figure 5-4B), along with primary tumor weight (Figure 5-4C and Figure 5-4D). We 
next measured by ELISA the concentration of serum active and total TGF-β in 
tumor bearing mice and we observed a drastic reduction of the mature form of 
TGF-β (Figure 5-4E) in parallel with an increase of the total form of the same 












Figure 5-4 Targeting platelet-derived GARP/TGF-β complex improves MC38 
tumor control. A. WT or Platelet GARP KO mice (n=5 each group) were injected 
in the right flank with 1x106 MC38 colon cancer cells. Tumor size was measured 
every 3 days with digital vernier caliper. B. Kaplan-Mayer survival curve in MC38-
bearing mice. C. In a separate experiment, 6 weeks after MC38 injection, mice 
were sacrificed and the primary tumors were resected and weighed. D. The inset 
shows the photographs of primary tumors resected from mice 6 weeks after 
injection. Serum was obtained from mice 6 weeks after MC38 injection and E. 
active and F. total TGF-β1 was measured by ELISA. Repeated measures two-way 
ANOVA was used in panel A; Kaplan-Meier curves and log rank tests were used 




Targeting platelet-derived GARP/TGF-β complex results in reduction of TGF-β 
activity in the tumor microenvironment 
 
Physiologically, cancer represents non-healing wound where the 
coagulation cascade forms a fibrin cloak where platelets are constantly 
activated147. We therefore reasoned that GARP effect on TGF-β derived platelets 
would have been obvious within the tumor. For this reason, tumors from WT and 
Pf4creGARPf/f mice were analyzed for active TGF-β signaling pathway. As 
expected, Smad3 phosphorylation was significantly increased in WT tumor when 
compared to tumors from Pf4creGARPf/f mice as shown by IHC pictures (5-5A) 
and score (5-5B). Accordingly, GARP abrogation in platelets impaired regulatory 




















Figure 5-5 Targeting platelet-derived GARP/TGF-β complex results in 
reduction of TGF-β activity in the tumor microenvironment. A. IHC for p-
SMAD-2/3 in MC38 tumors from indicated mice; representative images are shown. 
Scale bar: 12.5 m. B. Independent histopathological quantification of p-SMAD-
2/3 staining intensity from panel A (n=4 per group). C. Percentage of regulatory T 
cells CD25+ FOXP3+ in the CD4+ tumor-infiltrating lymphocytes (TIL) from the 

















Platelet GARP is increased upon thrombin stimulation and enhances active TGF-
β release in Platelets Releasate 
 
In the PR derived from human platelets stimulated with thrombin, TGF-β is 
one of the most abundant cytokines2. To study how platelet GARP modulates TGF-
β release and activation in PR, we stimulated WT and GARP KO platelets with 
thrombin and analyzed GARP expression and TGF-β activation status. Active 
platelets increased surface GARP/LAP expression of about 45%. Notably, LAP 
expression was also increased in activated GARP KO platelets, suggesting the 
upregulation of other latent TGF-β binding receptors, however the amount of latent 
TGF-β on GARP KO platelets was still less compared to activate WT platelets (5-
6A). Next WT and GARP KO platelets were isolated from peripheral blood and 
activated in presence or absence of thrombin (Figure 5-6B). Western blot analysis 
of the resulting PR revealed that upon thrombin stimulation GARP on platelets 
enhances the release of total as well as active TGF-β. (Figure 4-6C). Furthermore, 
TGF-β ELISA performed on the PR confirmed that GARP is critical for activation 
of the TGF-β released in PR (Figure 5-6D left panel), while the amount of total 
TGF-β was not affected by the lack of GARP (Figure 5-6D right panel). We next 
hypothesized that just like in Treg, GARP could be also be released from activated 
platelets as soluble protein in the PR. For this reason, we stimulated murine WT 
platelets with increasing units of mouse thrombin, collected the PR and analyzed 
GARP by Western Blot. Strikingly, we observed soluble GARP in PR in response 
to thrombin in the dose-dependent fashion (Figure 5-6E). Accordingly, further 
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ELISA data showed that GARP was released in PR only upon thrombin mediated 












Figure 5-6 Platelet GARP is increased upon thrombin stimulation and 
enhances active TGF-β release in Platelets Releasate. A. Flow cytometry 
analysis of surface GARP/LAP complex on WT and GARP KO platelets with and 
without thrombin stimulation. B. Schematic representation of the passages 
required for PR isolation. C. PR from WT and GARP KO platelets was obtained 
with and without thrombin stimulation. PR was analyzed by western Blot in non-
reducing and non-denaturing conditions. D. PR from WT and GARP KO platelets 
was obtained with and without thrombin stimulation. TGF-β was quantified by 
ELISA. E. PR from WT animals was stimulated with increasing concentration of 
Thrombin and analyzed by WB in reducing and denaturing conditions. F. PR from 
WT and GARP KO platelets was obtained with and without thrombin stimulation. 
Soluble GARP was quantified by ELISA. Two-tailed, independent Student’s t-test was 





















Direct thrombin inhibitor Dabigatran Etexilate reduces platelet GARP expression 
and protects against melanoma and colon cancer 
 
So far we have demonstrated that thrombin-stimulated platelets release 
active TGF-β through the mediation of GARP. Now, to establish the clinical 
relevance of the Thrombin-GARP/TGF-β axis we employed the direct thrombin 
inhibitor, Dabigatran Etexilate. Flow cytometry analysis of thrombin activated 
platelets shows that the increase of GARP expression on platelets can be 
neutralized by the inhibitory activity of Dabigatran (Figure 5-7A). We than tested 
the anti-tumor efficacy of Dabigatran Etexilate in 2 different tumor models. 
Strikingly we observed that Dabigatran reduced B16-F1 tumor aggressiveness 
even in absence of adoptive T cells transfer (Figure 5-7B). The efficacy of 
Dabigatran was then tested with MC38 colon carcinoma where, as well as B16-
F1, the sole direct inhibition of thrombin was sufficient to decrease the rate of tumor 
growth (Figure 5-7C). As a further proof of the mechanism employed by dabigatran 
to exert its antitumor activity, serum active and total TGF-β, and serum GARP 
concentrations were assessed by ELISA. Even though not statistically significant 
the pool of active TGF-β was drastically reduced: the mean observed in untreated 
mice was 101.3 ± 26.59, versus 42.47 ± 23.73 in Dabigatran treated mice. 
Similarly, blocking thrombin mediated platelets activation reduced serum total 
TGF-β (Figure 5-7E). Notably, Dabigatran impairs the released of serum soluble 
GARP from platelets (Figure 5-7F) and reduces the TGF-β mediated induction of 






Figure 5-7. Direct thrombin inhibitor Dabigatran Etexilate reduces platelet 
GARP expression and protects against melanoma and colon cancer. 
A. Flow cytometry analysis of surface GARP/LAP complex on murine WT platelets 
stimulated with and without thrombin and dabigatran etexilate. B. Tumor growth 
curves of mice subcutaneously injected with B16-F1 melanoma cells and daily 
treated with 3 mg/mouse of dabigatran etexilate.  C. Tumor growth curves of mice 
subcutaneously injected with MC38 colon cancer cells and daily treated with 3 
mg/mouse of dabigatran etexilate. D. Serum was obtained from tumor bearing 
MC38 colon cancer and active and total TGF-β1 (E) was measured by ELISA. F. 
Serum was obtained from tumor bearing MC38 colon cancer and soluble GARP 
was measured by ELISA. G. Percentage of regulatory T cells CD25+ FOXP3+ in 
the CD4+ tumor-infiltrating CD4+ lymphocytes (TIL) from the indicated mice. Two-
tailed, independent Student’s t-test was used in panel D, E, F, and G. Repeated 
measures two-way ANOVA was used in panel A 
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Direct thrombin inhibitor Dabigatran Etexilate in combination with anti-PD1 
blockade antibody reduces tumor burden in MC38 tumor model 
 
Checkpoint blockade, alone or in combination with chemotherapy, antibody 
therapy, radiotherapy or cancer vaccine are demonstrating excellent results in 
multiple tumor models148,149. Interestingly, gene expression analysis of tumors that 
do not respond to checkpoint therapy show an increase in TGF-β signaling 
transduction pathways150. Additionally, mice harboring 4T1 breast cancer and 
treated with triple combination of PD1 blockade antibody with TGF-β blockade and 
radiotherapy achieved complete regression, indicating a synergistic effect of anti-
PD1 and anti-TGF-β blockade therapy151. These evidences raise the hypothesis 
that PD1 blockade antibody together with anti TGF-β might be a new and effective 
combinatorial approach against cancer.  We decided to use Dabigatran, and not 
TGF-β blocking antibody, in combination with PD1 blockade because by blocking 
thrombin and consequentially platelet activation, we would achieve both a drastic 
reduction of systemic TGF-β, and the abrogation of platelet-mediated tumor 
support. Platelets, indeed, secrete many other factors beyond TGF-β that facilitate 
tumor immune evasion.  Animals harboring palpable tumors were daily treated with 
3 mg/mouse dabigatran by oral gavage. Additionally, 200 µg of anti-PD1 blockade 
antibody was administered every 3 days starting on day 8 (Figure 5-8A). Single 
therapies alone were equally effective in reducing tumor growth, however mice 
treated with combination of anti-PD1 and Dabigatran achieved total regression 






Figure 5-8. Direct thrombin inhibitor Dabigatran Etexilate in combination 
with anti-PD1 blockade antibody reduces tumor burden in MC38 tumor 
model 
A. Experimental design for Dabigatran and PD1 blocking antibody combination 
therapy. B. Tumor growth curves of mice subcutaneously injected with MC38 colon 
cancer cells and treated with Dabigatran alone, with PD1 blocking antibody, with 
the combination of Dabigatran and PD1 blocking antibody or left untreated. C. 
Survival curve in MC38-bearing mice treated with Dabigatran alone, with PD1 
blocking antibody, with the combination of Dabigatran and PD1 blocking antibody 
or left untreated. Repeated measurement 2 way ANOVA was performed in B. Log-








The role of platelets in promoting cancer invasion has been previously observed152. 
As a chronic unhealed wound, cancer constantly activates the coagulation 
pathway that culminates with the generation of high concentration of thrombin 
leading to massive platelets activation153. The fibrin clot surrounds and confers a 
selective advantage to the growing tumor protecting it by the tumoricidal attack of 
NK130 neutrophils131, macrophages and CTLs132. One of the critical mediator of the 
tumorigenic nature of platelets is TGF-β that, with its immunosuppressive 
properties, dampens both adaptive and innate anti-tumor immunity. Several efforts 
have been made to describe the release and function of platelet derive TGF-β81, 
yet the mechanism behind its maturation is still elusive. In this study we showed 
that GARP enhances the activation of latent TGF-β released by platelets and in 
doing so potentiates platelet tumorigenic activity. We also showed for the first time 
that GARP is released in the PR of thrombin activated platelets. Furthermore, we 
demonstrated that the release of mature TGF-β is the last step of a new thrombin-
GARP/TGF-β axis that can be pharmacologically blocked by direct thrombin 
inhibitors. Studies with genetic ablation of GARP from platelets selectively have 
led to a clear conclusion that serum active TGF- depends on the platelet surface 
GARP/TGF- complex. The increased in serum total TGF-β observed in platelet 
GARP KO, mice might be explained as a compensatory mechanism operated by 
platelets failing to generate a mature form of the cytokine. This hypothesis is 
supported by the elevated level of L-Lactate observed in platelets Pf4creGARPf/f 
mice (Supplemental Figure 1). The decreased TGF-β signaling in TME highlighted 
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by the ablation of Smad3 phosphorylation is a strong evidence of the loss of 
functional TGF-β in mice with specific deletion of GARP on platelets. 
Mechanistically we were able to demonstrate the presence of a pathway where 
thrombin, enhances GARP/latent TGF-β expression on platelets that in turn results 
in more release of active TGF-β and GARP in the PR. Not only TGF-β, but soluble 
GARP also have immunomodulatory function, thus reinforcing the pro-tumorigenic 
PR activity70. Based on these findings, high concentration of circulating soluble 
GARP and TGF-β1 could be regarded as valuable biomarkers for sustained 
platelet activation. Accordingly, high level of serum TGF-β is a poor prognostic 
factor in several malignancies154,155 and plasma soluble GARP was increased in 
metastatic prostate cancer patients (See results section 4, Figure 4-8), reinforcing 
the concept of platelets and cancer bi-directional activation.  Based on our results 
it is reasonable to hypothesize that platelets PR is one of the major contributors to 
systemic circulating TGF-β and GARP pool in cancer patients. 
Consistent with the genetic studies, the pharmacological inhibition of thrombin was 
sufficient to recapitulate some of the effects seen in the genetic studies. We are 
aware that Dabigatran may not be able to phenocopy platelet-specific GARP 
deletion for two reasons: first, by blocking thrombin, Dabigatran reduces the 
increase, but not GARP baseline expression; second Dabigatran, by blocking 
thrombin active site, has a direct effect on the ability of the platelets to aggregate 
and to form the fibrin clot. This difference is evident in the reduction of both active 
and total serum TGF-β: mice treated with Dabigatran show a drop in both active 
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and total TGF-β, unlike Pf4creGARPf/f mice that experienced a drop in active, yet 
an increase in serum total TGF-β. Intriguingly, this last difference may shed light 
on the regulation of the two pools of TGF-β that are released by active platelets. 
As described earlier, Grainger and colleagues noticed that one pool of TGF-β is 
released in the serum as part of the LLC complex, the other pool instead is retained 
in the clot and is gradually released as active form. Since GARP KO platelets have 
normal thrombotic activity and the only phenotypic manifestation found in 
Pf4creGARPf/f mice is the ratio between total and active TGF-β, it is reasonable 
to conclude that platelet GARP plays its role in the release of active TGF-β from 
the fibrin clot. Dabigatran, on the other hand, by blocking both platelets 
aggregation and clot formation, acts earlier in the coagulation cascade, inhibiting 
the secretion of both pools of platelet-derived TGF-β. Additionally, it is noteworthy 
to mention the pro-tumorigenic effect exerted by other platelet soluble and 
membrane bound components. Dabigatran, indeed, inhibits the upregulation and 
expression and secretion of multiple oncogenic factors that would occur otherwise 
are upon platelets activation.   
The results from the combination therapy of Dabigatran Etexilate and PD1 
blockade strongly supports the notion that the efficacy of re-activated tumor-






Summary, Conclusions and Future Prospective 
 
Summary and Conclusions 
 
The importance and pleiotropic activity of TGF-β justifies the complexity and 
the multiplicity of mechanisms involved in its regulation. Multiple diseases, indeed, 
are a direct consequence or are exacerbated by defects in TGF-β regulation. 
Because of its tolerogenic properties, TGF-β is involved in infections clearance, 
cancer initiation, metastasis dissemination, and loss of tolerance to self-antigen in 
autoimmunity179.  
GARP protein has been previously described as a latent TGF-β receptor 
expressed on Tregs that enhances TGF-β activation and, as a consequence, 
impacts Tregs induction and function. This thesis has uncovered novel insights 
regarding GARP/TGF-β axis which might be potentially exploited in clinic.  
Initially results showed in chapter 3 offer two mechanisms to explain soluble GARP 
formation and signal transduction. In the first mechanism, unbiased informatics 
analysis revealed the presence of two different thrombin binding sites in GARP 
protein sequence. Our genetic studies then validated that thrombin is the enzyme 
that cleaves GARP and enables the formation of two soluble fragments. 
Mechanistically, we demonstrated that GARP cleavage mediates the release of 
latent TGF-β. We also observed that thrombin cleaves GARP on isolated platelets, 
suggesting the in vivo physiological relevance of this phenomenon. This novel 
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finding add insights into the role of thrombin in platelets stimulation: as a protein 
abundantly expressed on platelets, GARP cleavage might facilitate latent TGF-β 
release and activation in platelets releasate.  
Our functional studies with GFP p-SMAD3 reporter cell line, show that soluble 
GARP relies on αV integrins to elicit TGF-β signal transduction and, surprisingly, 
to be internalized. This unexpected phenotype might suggest that soluble GARP 
signal transduction is mediated by endocytosis with the subsequent release of 
mature TGF-β in the acidic vesicles.  
Finally, we clearly showed that GARP in complex with TGF-β is abundantly 
secreted in the exosome cargo, unveiling another novel aspect of GARP biology 
in the process of mediating intercellular communication and tolerance.  
In chapter 4, we observed GARP expression in several aggressive human 
cancers. Mechanistically, we showed that i) GARP/TGF-β axis makes cancer cells 
acquire oncogenic properties and that ii) enforced GARP expression leads to the 
amplification of active TGF-β signaling in TME. The accumulation of active TGF-β 
in TME was evidenced by Smad3 phosphorylation and expansion of tolerogenic 
Treg cells. Additionally, our data showed that soluble GARP in plasma of cancer 
patients is elevated and its level directly correlates with cancer stage.  
After analyzing function of GARP/TGF- expression on cancer cells, in chapter 5 
we decided to investigate the role played by GARP on platelets. We reasoned that 
platelets are a perfect model for our research since they abundantly express 
surface GARP/latent TGF-β1 and because platelets are the biggest TGF-β 
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reservoir in the body. Strikingly, GARP on platelets regulates the balance between 
serum active and latent TGF-β: genetic deletion of GARP from platelets ablates 
active TGF-β while increasing its latent form. This might suggest a constant 
platelets activation status (as indicated by higher serum lactic acid) to compensate 
for lacking of mature TGF-β. Using two different cancer models we discovered that 
GARP exacerbates platelets-induced tumor growth because of enhanced TGF-β 
activation in platelets releasate. Additionally, for the first time we identified that, 
upon platelets activation, soluble GARP is released by platelets. This finding might 
explain why cancer patients, who experience sustained platelets activation, have 
high concentration of GARP in their plasma. It is also possible that this platelet-
derived soluble GARP adds up to the soluble GARP released by cancer cells.  
In a clinically relevant system, we then decided to block platelet GARP/TGF-β axis 
using Dabigatran, a direct thrombin inhibitor approved by the FDA for stroke 
prevention. Our results show that blocking thrombin was therapeutic beneficial 
against two cancer models, especially in combination with checkpoint blockade 
treatment.  This last observation is important especially because intratumoral TGF-
β has been showen to be one of the reasons responsible for checkpoint blockade 









Clinical Translation  
 
The results reported in this thesis offer a wide range of translational options. 
First, GARP as tissue tumor biomarker is a valuable prospective especially for 
those tumors, like prostate carcinoma, that do not have consistent tissue 
biomarkers180. Second, we also observed a good correlation between plasma 
soluble GARP and tumor aggressiveness in prostate cancer patients indicating 
that the amount of soluble GARP is a good indicator of tumor status and anti-
cancer treatment efficacy. Again, this is especially true in prostate cancer where 
the only existing liquid biomarker PSA1 (Prostate Specific Antigen 1) is known to 
associate with problems in specificity and sensitivity 181.  
Moreover, we envision GARP as an attractive target for tumor antibody based 
therapy. Anti-GARP antibody, alone and in combination with cyclophosphamide, 
indeed showed anti-metastatic potentials in murine mammary tumors1. 
Importantly, targeting GARP on cancer cells has the favorable side effect to reduce 
the immunosuppressive ability of Treg. This effect has been already demonstrated 
by another investigator showing that monoclonal GARP antibody restrains Treg 
immunosuppressive activity in GVHD69. Additionally, we do not underestimate the 
importance of the blocking activity that GARP antibody might exerts on soluble and 
exosomes bound GARP/TGF-β complex.   
Another exciting translational potential is represented by the combination of anti-
platelets agents and anti-tumor therapy. We have proposed Dabigatran Etexilate 
as inhibitor of thrombin-mediated platelets activation, in combination with PD1 
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blockade antibody. Our results demonstrate that Dabigatran Etexilate reduces the 
accumulation of intratumoral TGF-β which potentiates checkpoint blockade 
therapy. 



















This work, while answering several aspects of GARP biology, raises many 
unanswered and provoking questions. Several investigators using numerous 
models largely demonstrated that GARP enhanced TGF-β activation, yet the 
intimate mechanism for mature TGF-β release is still elusive. The discovery of 
thrombin mediated GARP cleavage unveils a novel protease-dependent 
mechanism of TGF-β maturation that requires more investigation to be fully 
understood. Our results show that the complete activation of TGF-β seen in 
platelets releasate, is not achievable by the sole GARP/latent TGF-β complex 
digestion with thrombin. This indicates that another components or other pathways 
present in platelets are critical for the final step of TGF-β activation.  In this regards 
we plan to explore i) the signal transduction initiated by thrombin receptor 
engagement, ii) the role of integrins expressed on platelets, iii) the effect of the 
acid environment in which latent TGF-β is released, and  iv) the possibility of a role 
played by GARP, that with the intracellular domain, might engage an unexplored 
signaling pathway. This latter possibility has never been evaluated, since the 
shortness and the lack of obvious binding motifs in the GARP cytoplasmic tail. 
However, as mentioned earlier, human and mouse GARP share a conserved 
tyrosine residue that is also present in TLRs where it acts as a part of a signal 
transduction.   
Additionally, we are the first to observe integrin-mediated soluble GARP 
internalization and signal transduction.  This observation indicates the possibility 
that GARP, other than acting as a surface receptor, plays an intracellular function.  
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For this reason, we intend to investigate the role of the acidic endosomal 
compartment in the degradation of GARP/TGF-β complex and in the release of 
mature TGF-β. 
Finally, the presence of GARP/TGF-β complex in exosomes suggests that GARP 
mediates the intercellular diffusion of TGF-β. The implications of this novel 
discovery in cancer and immune tolerance will be addressed in the immediate 












Supplemental Figure 1. Serum L-lactate increases in Pf4creGARPf/f mice 











Supplemental Figure 2. GARP is released in the plasma when the anti-tumor 
therapy is effective. Comparison of Plasma GARP and PSA1 level during 5 
cycles of Androgen deprivation therapy. Similar trend was observed in 16 over 36 
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